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Abstract 
The common neurodegenerative disorder Parkinson’s disease (PD) affects millions of people 
world-wide. The disease is characterized by slow, progressive, and age-dependent neuronal cell 
death, most pronounced in a particularly vulnerable subset of dopamine-containing neurons in 
the substantia nigra (SN), which are involved in locomotor control. While the etiology is still 
largely unknown, during the last decade a number of genetic mutations that cause inheritable 
forms of the disease have been mapped. Surprisingly, knockout mouse models of three genes 
causing autosomal recessive PD (ARPD) - Parkin, PINK1 and DJ-1; show no overtly 
degenerative phenotypes.  
Another group of proteins that has been connected to the survival of dopamine neurons is the 
neurotrophic factors and their receptors. Glial cell line-derived neurotrophic factor (GDNF) 
signals via the co-receptor GDNF family receptor α1 (GFRα1) and the receptor tyrosine kinase 
rearranged during transfection (Ret). GDNF treatment in animal models of PD has proven to 
protect against cell death, moreover, GDNF and Ret are physiologically required for survival of 
dopamine neurons, since conditional ablation of GDNF or Ret causes neurodegeneration. 
However, how GDNF/Ret signaling promotes survival of dopamine neurons remains unknown. 
In this project, I studied the functions of Ret signaling in different models of ARPD, with the 
hypothesis that Ret co-operates with ARPD-associated genes in maintaining critical cellular 
functions.  
I participated in a study that, using mouse genetics, found that combined ablation of Ret and the 
ARPD-associated gene DJ-1 causes increased loss of SN neurons compared to Ret and DJ-1 
single mutants in a synergistic manner, indicating that DJ-1 is required for survival of neurons 
that are impaired in receiving trophic support. In cell culture, I investigated cellular pathways 
that could biochemically link Ret signaling to DJ-1 function. It was previously reported that DJ-
1 positively regulates Akt and Erk phosphorylation. However, by depleting or overexpressing DJ-
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1 in HeLa, SH-SY5Y, COS7, and A549 cells, or by comparing wildtype and DJ-1 knockout 
fibroblasts, I found no evidence supporting either of the two previously reported findings. 
 
I also hypothesized that Ret signaling can compensate for the loss of two other ARPD-associated 
genes, Parkin and PINK1, which function in controlling mitochondrial integrity. Depleting 
Parkin and PINK1 from mammalian cells is known to cause mitochondrial fragmentation, and 
here I found that this can be reversed with GDNF treatment. 
 
Furthermore, I investigated whether this function of Ret is conserved in the fruit fly Drosophila 
melanogaster. Mutants for park and Pink1 have enlarged and dysfunctional mitochondria in 
several tissues, together with degenerated indirect flight muscles (IFMs), including abnormal 
myofibrils. Overexpression of a constitutively active version of the Drosophila homolog of Ret 
(DretMEN2A) did not rescue the mitochondrial deficiencies of park and Pink1 mutants in 
dopamine neurons or IFMs. However, DretMEN2A/B overexpression also caused abnormal 
myofibrils, and interestingly, I found that DretMEN2B functioned in partial epistasis with Pink1, 
and restored myofibrillar abnormalities in Pink1 mutants. 
 
Finally, I asked whether combined ablation of Ret and Parkin or Ret and PINK1 in dopamine 
neurons of mice causes increased neurodegeneration upon aging, compared to Ret single 
mutants. Unexpectedly, all combinations of mutants, as well as Ret single mutants, were devoid 
of degeneration up to 24 months of age, indicating that other additional factors may be required 
to sensitize Ret mutants for them to develop a neurodegenerative phenotype. 
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1. Introduction 
1.1. Background to Parkinson’s disease 
1.1.1. Clinical manifestation and neuropathology 
Parkinson’s disease (PD), first described by the British physician James Parkinson in 1817 
(Parkinson 1817), is the second most common neurodegenerative disorder, affecting an 
estimated 1-2 % of the population older than 65 years. For people older than 85 years, the 
prevalence increases to 5 %, and as the average life span of the population in the developed world 
steadily increases, it is predicted to become an even greater problem for society in the future (Van 
Den Eeden et al. 2003; de Lau & Breteler 2006). The cardinal clinical feature of PD is the so-
called parkinsonism syndrome, which is defined by resting tremor, bradykinesia (slowness of 
movement), postural instability and rigidity. In addition to the motoric symptoms, patients 
commonly present with cognitive and psychiatric problems such as anxiety or depression, and 
even symptoms related to peripheral autonomic nerves such as constipation (Stanley Fahn 2003). 
Pathologically, the disease is characterized by neurodegeneration, most pronounced in the 
dopamine (DA) neurons of the substantia nigra pars compacta (SNpc), which form the 
nigrostriatal pathway, together with depletion of dopamine in the striatum, which also is the 
cause of parkinsonism. Another hallmark of the disease is the presence of cytoplasmic 
proteinaceous inclusions in remaining SNpc neurons, so-called Lewy bodies, as well as dystrophic 
neurites, known as Lewy neurites (Lewy 1912). A thorough neuropathological post-mortem 
analysis by Braak and colleagues found Lewy pathology in vast areas of the brain, and by 
analyzing PD patients of different progression they proposed a staging system of the pathology, 
with the earliest pathology found in the dorsal motor nucleus of the vagal nerve and Raphe 
nuclei of the lower brain stem. From there, it appeared to progress rostrally to the SN and ventral 
tegmental area (VTA) in the ventral midbrain, and later continued to the amygdala, 
hippocampus and neocortex (H. Braak et al. n.d.). The large Lewy body aggregates contain 
several different proteins; however, the main components are α-synuclein and ubiquitin. The 
mechanism of aggregate formation is an intensively studied topic, but it remains unclear whether 
the aggregates are pathological themselves or merely an inert byproduct. In particular, α-
18  

synuclein oligomeric species have attracted particular interest as they appear to be toxic (Venda et 
al. 2010). 
1.1.2. Current and developing treatment options 
Major leaps towards understanding the pathology of PD and the development of therapy were 
taken in the late 1950’s and 1960’s with research by Swedish neuroscientist Arvid Carlsson, as he 
discovered that dopamine is in fact a neurotransmitter and not just a precursor in the 
noradrenaline synthesis. When he treated mice with the drug reserpine, a vesicular monoamine 
transporter (VMAT) inhibitor, they showed reduced dopamine levels and developed 
parkinsonism symptoms. This finding led him to administer the dopamine precursor L-dopa to 
reserpine-treated mice, and with that he was able to alleviate the symptoms (Carlsson et al. 
1957). Still today, more than 50 years after this discovery, L-dopa-based pharmaceuticals are the 
primary therapy for PD patients. During the last decade, a new therapy of deep brain stimulation 
(DBS) has proven effective in later stage-patients, which aims at directly modulating the basal 
ganglia circuitry by electrical currents. Both dopamine-replacement therapy and DBS can 
ultimately only alleviate symptoms (and in that, only the motoric symptoms), but cannot halt 
disease progression.  
 
Cell replacement therapy has for the past thirty years been under development and some early 
open-label transplantation studies using fetal midbrain cells have had successful outcomes 
(Lindvall et al. 1990; Freed et al. 1992). However, later, double-blinded trials showed no 
statistical improvement compared to sham surgery (Freed et al. 2001; Olanow et al. 2003). The 
possibility of cell replacement has boosted the field of stem cell research, with a view to 
developing sources of cells for transplantation. However, even with recent tremendous advances 
the road to functionally and safely restoring the nigrostriatal tract in PD patients will be long 
(Arenas 2010; Wakeman et al. n.d.). Another developing approach aims at neuroprotection using 
neurotrophic factors. The US National Institutes of Health is currently conducting a phase II 
clinical trial for the use of glial cell line-derived neurotrophic factor (GDNF) administered by 
gene therapy and the US biotechnology company Ceregene has recently started phase II trials of 
the GDNF homolog neurturin. The biological basis for neurotrophic factor-based therapies is 
discussed further in section 1.3. 
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1.1.3. Nigrostriatal dopamine neurons – function and selective vulnerability 
The human and mouse brains contain eleven groups of dopamine cell bodies, the majority of 
which are located in the midbrain, basal ganglia and olfactory bulb, as illustrated by an in situ 
hybridization (ISH) for the dopamine neuron marker tyrosine hydroxylase (Allen Brain Atlas, 
figure 1-1a). Dopamine receptors, indicating post synapses for dopamine neurons, are found 
mainly in the striatum, neocortex and olfactory bulb, as illustrated by D1A receptor ISH (Allen 
Brain Atlas, figure 1-1b). The ventral midbrain can be separated into VTA, involved in reward 
circuitry, and the SN, involved in motor control. The SN can in turn be divided in the pars 
compacta (pc), the neurons of the nigrostriatal pathway, and the pars reticulata (pr), projecting to 
the thalamus. The compacta neurons are also not a fully homogenous cell population. The 
expression of two marker proteins, the G-protein-activated inward rectifier potassium channel 
(GIRK2) and the calcium binding protein calbindin, mark two subsets of ventral midbrain 
neurons. The two populations do partly, but not fully, correspond to the anatomical division of 
SNpc and VTA, and show little overlap (Allen Brain Atlas, figure 1-1c). GIRK2+ neurons make 
up approximately 75 % of the SNpc and project to the putamen in the dorsal striatum, where 
they control locomotion, while the remaining 25 % calbindin+ neurons project to limbic and 
Figure 1-1 Dopaminergic cells of the mouse brain. In situ-hybridizations of (a,b) sagittal-sectioned mouse brains, 
for (a) tyrosine hydroxylase, indicating DA neuron cell bodies, (b) dopamine receptor D1A, indicating DA neuron 
synapses, and of (c) coronal sectioned mouse ventral midbrains for GIRK2 or calbindin-d28k with the ventral 
tegmental area (VTA) and substantia nigra (SN) depicted. All images were taken from the Allen Brain Atlas
(www.brain-map.org).  
Tyrosine hydroxylase Dopamine receptor D1A
GIRK2 Calbindin-d28k
SN
VTA
SN
VTA
a b
c
Midbrain 
DA neurons
Striatum
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neocortical areas (Björklund & Dunnett 2007). The striatum, SN, basal ganglia and thalamus 
together form a circuitry that fine-tunes locomotion (figure 1-2a). The SNpc neurons synapse in 
the striatum with both the excitatory D1 type of dopamine receptors, a part of the ‘direct 
pathway’ which increases movement, and also with the inhibitory D2 type of receptors, which 
function in the ’indirect pathway’ that decreases movement (Rodriguez-Oroz et al. 2009). In 
Parkinson’s disease, both the D1 and D2 projections are lost, causing a subsequent increase in 
the indirect pathway signaling, and a decrease in the direct pathway signaling (figure 1-2b). In a 
recent study, researchers were able to directly activate the D1 or D2 receptor expressing striatal 
neurons individually, using optogenetics (Kravitz et al. 2010). When D1 expressing neurons were 
activated, mice became hyperactive, and when activating the D2 expressing neurons, mice 
instantly showed typical parkinsonism-type movements, proving the validity of this model.  
 
The axonal projections of SNpc neurons are believed to be affected first in the degenerative 
process as the striatum is depleted of dopamine (Bernheimer et al. 1973), and this has led to a 
dying-back model of degeneration (Dauer & Przedborski 2003). Interestingly the SNpc neurons 
are more affected in PD, showing a higher level of cell death, than the VTA neurons (Uhl et al. 
1985). Similarly calbindin+ neurons are relatively spared in comparison to GIRK2+ neurons in 
animal models of PD (C. L. Liang et al. 1996; C. Y. Chung et al. 2005). What causes this 
difference between DA neuron cell types adjacent to each other in the ventral midbrain? One 
possibility is that their diverse projections make the difference, as activities or signaling in the 
target area may render them more or less sensitive. Another possibility lies in their physiology 
and gene expression, irrespective of projections. It is possible that calbindin expression is 
protective, or alternatively that GIRK2 expression sensitizes them, a theory that is supported by 
the finding that GIRK2 overexpression in PC12 cells renders them more vulnerable to toxin 
treatment (C. Y. Chung et al. 2005). An intriguing series of research from the Surmeier 
laboratory has focused on the regional selectivity of SNpc neuron cell death. They found that 
SNpc neurons, as opposed to VTA neurons express a pace making L-type calcium channel 
(CaV1.3), and when this channel is selectively blocked in mice, SNpc neurons were protected 
from toxin-induced cell death (C. S. Chan et al. 2007). 
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1.1.4. Etiology and genetics of PD 
PD is a complex multifactorial disorder, of which aging, genetics and environmental factors all 
increase disease risk. The majority of cases (estimated as up to 90 %) is sporadic, also known as 
idiopathic, and can vary to a large extent in the expression of symptoms. The pathogenic agents 
behind these cases are still largely unknown. In 1983 mitochondrial toxicity was first linked to 
PD, when a group of opioid drug abusers all presented with parkinsonism symptoms, which 
could be tracked back to the accidental intake of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
(MPTP), with the active metabolite 1-methyl-4-phenylpyridinium (MPP+), which interferes 
with complex I of the mitochondrial electron transport chain (Langston et al. 1983). 
Epidemiological studies suggest that environmental toxins, such as the pesticide rotenone, 
another mitochondrial complex I inhibitor, or the herbicide paraquat may be involved, but 
strong evidence is missing (T. P. Brown et al. 2006). Further support for a central role of 
Figure 1-2 Circuitry of movement control by the basal ganglia. In a healthy brain (a), The striatum is innervated by
the motor cortex, but also by the substantia nigra pars compacta (SNpc), which forms synapses on two types of
neurons. The first type receives excitatory (blue arrows) DA input via dopamine D1 receptors, forming the direct
pathway. The second type receives inhibitory (red) input via dopamine D2 receptors, forming the indirect pathway.
The direct pathway further continues with inhibitory GABAergic neurons, which project to the globus pallidus pars
interna (GPpi) and substantia nigra pars reticulata (SNpr), which in turn contains inhibitory GABAergic neurons
projecting to the thalamus, which sends excitatory glutamatergic signals back to the motor cortex. Conversely, the
indirect pathway, continues with striatal GABAergic neurons that project to the globus pallidus pars externa (GPpe),
inhibiting the subthalamic nucleus (STN), which in difference to the direct pathway, sends excitatory input to the
GPpi and SNpr. In Parkinson’s disease (b), the SNpc neurons degenerate, causing a loss both D1 and D2 receptor
transmission in the striatum, which leads to decreased signaling via the direct pathway, and increased signaling via
the indirect pathway, in the end causing decreased excitation of the motor cortex.  
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mitochondria in the etiology of PD came from the ’MitoPark‘ mouse model, a dopaminergic 
conditional knockout of the mitochondrial transcription factor tfam gene, which develops a 
parkinsonian phenotype including progressive SNpc neuron degeneration, impaired motor 
function and intraneuronal inclusions (Ekstrand et al. 2007). 
 
It was long believed that PD was a non-genetic disorder, but successively autosomal-inherited 
Mendelian forms have been discovered, and during the later part of the 1990’s and early 2000’s, 
major breakthroughs in genetics lead to the identification of several distinct causative loci, the 
PARK genes. To date, up to 16 loci have been confirmed to cause PD or parkinsonism-like 
disorders  some dominant, others recessive, and the list continues to grow as new loci are 
frequently reported (table 1). The line between sporadic and genetic PD is becoming increasingly 
blurred, as loci only acting as risk factors for sporadic PD are discovered, such as the genes for 
microtubule-associated protein tau (MAPT) or glucocerebrosidase (GBA), which also causes 
Gaucher’s disease (Zabetian et al. 2007; Sidransky et al. 2009). Interestingly, genes of the 
Mendelian PARK loci, with complete disease penetrance of certain mutations, have recently 
turned up in genome-wide association studies (GWAS) as low-penetrant increased-susceptibility-
loci for sporadic PD with polymorphisms in different positions, further blurring the distinction 
between genetic and sporadic PD (Simón-Sánchez et al. 2009; Satake et al. 2009). In addition, 
there are several conditions such as spinocerebellar ataxia, Wilson’s disease, and frontotemporal 
dementia that can present with parkinsonism. Another complicating factor of studying genetic 
PD, is the fact that different PARK loci cause syndromes with considerable differences in their 
neuropathology, clinical symptoms, and age of onset. For example, the autosomal-recessive PD 
(ARPD) forms, PARK2, PARK6, and PARK7 discussed in detail later in this thesis, differ 
significantly from sporadic and autosomal-dominant forms with very early ages of onset, and 
symptomologies restricted to parkinsonism. The mutations of these three genes all appear to 
result in loss of function, and therefore studying the function of such genes can hopefully teach 
us something about the mechanisms behind dopamine neuron cell death. Even though these 
recessive forms differ from sporadic PD, the two likely share mechanistic features. Linking the 
disease-causing pathways of recessive PARK genes and toxin models such as MPTP, which all 
seem to be connected to mitochondrial pathology, with the protein misfolding and aggregation 
pathway observed in α-synuclein (SNCA) and leucine-rich repeat kinase 2 (LRRK2) PD, as well as 
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in sporadic disease, remains an unsolved issue for PD research, and may be fundamental in our 
understanding of the pathogenic process.  
 
Table 1-1 Genes associated with monogentic inherited PD 
PARK-locus Location Gene Inheritance Protein function 
PARK1/4 4q21-q23 SNCA (point mutation/triplication) AD Synaptic vesicle transport 
PARK2 6q25.2-q27 parkin AR E3 Ubiquitin ligase 
PARK3 2p13 unclear AD  
PARK5 4p14 UCHL1 AD Ubiquitin hydrolase 
PARK6 1p35-p36 PINK1 AR Mitochondrial kinase 
PARK7 1p36.33 - p36.12 DJ-1 AR Oxidative stress sensor 
PARK8 12p11.23-q13.11 LRRK2 AD Multidomain-kinase 
PARK9 1p36 ATP13A2 AR Cation-transporting ATPase 
PARK10 1p32 unclear unclear  
PARK11 2q36-q37 GIGYF2 AD GRB10 interactor 
PARK12 Xq21-q25 unclear X-linked  
PARK13 2p12 HTRA2 AD Mitochondrial serine peptidase 
PARK14 18q11 PLA2G6 AR Phospholipase 
PARK15 22q12-q13 FBXO7 AR F-box, ubiquitination component 
PARK16 1q32 unclear unclear  
1.2. Functions of ARPD-associated proteins 
1.2.1. DJ-1 functions as a redox sensor, and as a regulator of transcription, translation and signal 
transduction pathways 
The first reports on DJ-1 were concerned with oncogenic activity, as DJ-1 had been found to be 
upregulated in cancers and to have transforming activity in cell culture (Nagakubo et al. 1997; Le 
Naour et al. 2001). PD-linked mutations in the DJ-1 gene (PARK7) were initially identified in 
two independent families (Bonifati et al. 2003), but are an extremely rare cause of PD as was 
demonstrated by a recent study (Anvret et al. 2011). The DJ-1 protein has puzzled researchers 
for several years, due to apparent difficulties in elucidating its true physiological function and role 
in PD-pathogenesis. Even though an astonishing number of molecular functions have been 
reported, most of the studies are based solely on cell culture data and it remains elusive which 
functions are physiologically relevant in vivo. It would be impossible to describe every function 
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that has been reported, however a selection of them are described and illustrated below (figure 1-
3).  
 
The 189 amino acid small protein (figure 1-4), found natively as a dimer, shares some homology 
with the ThiJ/PfpI family of bacterial molecular chaperones, and indeed chaperone activity for 
DJ-1 has been reported (Shendelman et al. 2004; Deeg et al. 2010; Bandyopadhyay & Cookson 
2004). The most conclusive finding about DJ-1 function is that it responds to, and protects 
against, oxidative stress-induced cell death (Taira et al. 2004; Canet-Avilés et al. 2004; Martinat 
et al. 2004; Meulener et al. 2006; Görner et al. 2007). DJ-1 has a highly conserved cysteine 
residue (human DJ-1 C106) that reacts with reactive oxygen species to form a sulfonic acid 
group upon oxidative stress (Canet-Avilés et al. 2004; Kinumi et al. 2004; Ooe et al. 2006; 
Andres-Mateos et al. 2007; Hulleman et al. 2007). Details of the response to oxidation of this 
cysteine residue remains to be clarified, but interestingly it was shown to be critical for DJ-1-
mediated protection against MPP+ (Canet-Avilés et al. 2004). The same study also found that 
DJ-1 translocated to mitochondria during oxidative stress, and recently, it was shown that 
oxidized DJ-1 interacts with b-cell lymphoma extra large (Bcl-XL)  (Ren et al. 2011). In addition 
to functioning as a chaperone and reacting to oxidative stress, many other functions have been 
reported: DJ-1 was found to bind to p53 and either repress (J. Fan, Ren, Jia, et al. 2008; J. Fan, 
Ren, Fei, et al. 2008; Bretaud et al. 2007) or enhance (Shinbo et al. 2005) its transcriptional 
activity. Furthermore, DJ-1 was reported to bind and regulate the androgen receptor (Tillman et 
al. 2007; K Takahashi et al. 2001), to have protease activity (Koide-Yoshida et al. 2007), act as a 
transcription factor for tyrosine hydroxylase (TH) (J. Xu et al. 2005), and regulate transcription 
of antioxidant response factors by stabilizing the kelch-like ECH-associated protein 
(Keap1)/nuclear respiratory factor 2 (Nrf2) transcription activation complex (Clements et al. 
2006). However, this finding could not be reproduced in another study (L. Gan et al. 2010). 
Moreover, DJ-1 was found to act as a peroxiredoxin-like peroxidase (Andres-Mateos et al. 2007), 
regulate translation by directly binding GC-rich mRNA (van der Brug et al. 2008; Blackinton et 
al. 2009), interact with the protein kinases MEK kinase 1 (MEKK1) and homeodomain-
interacting protein kinase 1  (HIPK1) (Mo et al. 2008; Sekito et al. 2006), and regulate apoptosis 
signaling kinase-1 (Ask1) by sequestering its activator death-associated protein 6 (DAXX) (Junn 
et al. 2005). Interestingly DJ-1 was reported to promote Akt signaling, one of the major pro-
survival signaling pathways activated by receptor tyrosine kinases, by negatively regulating 
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phosphatase and tensin homolog (PTEN) (Y. Yang et al. 2005; R. H. Kim, Peters, et al. 2005). 
Recently, DJ-1 was also reported to increase extracellular signal-regulated kinase 1/2 (Erk1/2) 
phosphorylation (L. Gu et al. 2009). Yet another role for DJ-1 was reported when it was found 
that it can control mitochondrial dynamics (Kamp et al. 2010; K. J. Thomas et al. 2011). DJ-1  
was also found to bind to two of the other ARPD-associated proteins, Parkin (D. J. Moore et al. 
2005) and PTEN induced putataive kinase 1 (PINK1) (Tang et al. 2006).  
At least five independent DJ-1 knockout mouse lines have been generated, but in contrast to 
PARK7 PD patients, DJ-1 knockout mice do not display any loss of SNpc DA neurons or loss of 
striatal DA fibers (R. H. Kim, P. D. Smith, et al. 2005; Goldberg et al. 2005; Linan Chen et al. 
2005; Chandran et al. 2008; Yamaguchi & J. Shen 2007). The mice did show subtle behavioral 
alterations, for example reduced activity, and one study also found impairments in striatal 
Figure 1-3 Reported biochemical functions of DJ-1. DJ-1 was reported to respond to oxidative stress, and regulate a 
number of signal transduction pathways including PI3K-Akt, MEKK1-JNK, Ras-Erk, and DAXX-Ask1. In 
addition, DJ-1 was reported to regulate transcription by binding to p53 and Keap1/Nrf2. DJ-1 has been shown to 
localize to mitochondria and interact with Bcl-Xl. DJ-1 was also found to interact biochemically with the other
ARPD associated proteins PINK1 and Parkin. 
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dopamine D2 receptor function, with absence of long-term depression (LTD), and reduced 
synaptic dopamine release (Goldberg et al. 2005). Guzman et al found that DJ-1 mutant mice 
show increased sensitivity to pacemaking calcium transients, due to decreased mitochondrial 
uncoupling, and that DJ-1 upregulates uncoupling protein 4/5 (Guzman et al. 2010), proposing 
a model that explains why SNpc neurons are selectively vulnerable to DJ-1 mutations.  
How can a small protein with limited functional domains perform all of these greatly varied 
functions? One possibility is that many of the observed effects of regulating various pathways are 
secondary to one major function, such as controlling a transcriptional master regulator, which 
again also was reported, for example with p53 and Nrf2, but many of the functions above could 
still not be explained by such a mechanism. Further studies are required to clarify which of the 
biochemical effects found in vitro are physiologically relevant in vivo. Such a clarification could 
shed important light on the etiology of PARK7 PD. 
1.2.2. The E3 ubiquitin ligase Parkin 
The most common causes of ARPD are mutations in the PARK2 locus, which harbors the parkin 
gene first mapped in 1998 (Kitada et al. 1998). Parkin mutations are estimated to account for 50 
% of all ARPD cases (Lücking et al. 2000) and are also frequently found in sporadic cases 
(Periquet et al. 2003). The highly conserved and ubiquitously expressed Parkin protein belongs 
to the family of E3 Ubiquitin ligases, and contains three Really interesting new gene (RING) 
domains, with an in-between RING domain, and a N-terminal ubiquitin-like domain (figure 1-
Figure 1-4 Domain structures of DJ-1, Parkin, and PINK1. The DJ-1 protein (189 amino acids) lacks known 
functional motifs, but harbors a cysteine residue (C106), that is oxidized by reactive oxygen species. Parkin (465 
amino acids) contains a ubiquitin-like domain (UBL), three RING domains and one in-between-RING domain. 
PINK1 (581 amino acids) contains a mitochondrial target sequence (MTS), a transmembrane domain, and a
Ser/Thr kinase domain. 
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4). As such, Parkin can form complexes with several E2 ligases and can mediate both K48 and 
K63 polyubiquitination (Doss-Pepe et al. 2005).  
1.2.3. Non-mitochondrial targets of Parkin 
The literature on Parkin is far less divergent than in the case of DJ-1, since its E3 ligase function 
is clear, but still many different targets have been reported (figure 1-5). Recently a mitochondrial 
function for Parkin in cooperation with PINK1 has emerged and is described in sections 1.2.5-6. 
However, apart from a function in mitochondria, several other interesting findings have been 
made: Imai et al reported in two studies that Parkin ubiquitinates unfolded Parkin-associated 
endothelin-like receptor (PAEL-R) in a complex with C terminus of HSC70 interacting protein 
(CHIP) and heat shock protein 70 (HSP-70), which otherwise may cause endoplasmic reticulum 
(ER) stress-induced cell death, placing Parkin in the unfolded protein response (UPR) system (Y. 
Imai et al. 2001; Y. Imai et al. 2002). Corti et al reported that Parkin ubiquitinates the aminoacyl 
transferase p38 (Corti et al. 2003). Interestingly, Parkin has also been shown to target a specific 
glycosylated form of α -synuclein (α -sp22), which is accumulated in Parkin-deficient brains, 
providing a functional link between α -synuclein aggregation and parkin-linked PD (Shimura et 
al. 2001). Later, it was also found that Parkin could bind LRRK2 (W. W. Smith et al. 2005), 
DJ-1 (D. J. Moore et al. 2005) and recently PINK1 (Matsuda et al. 2010; Vives-Bauza et al. 
2010; Narendra et al. 2010). Furthermore, it was shown that Parkin upregulates endothelial 
growth factor receptor (EGFR) signaling by ubiquitinating the endocytosis mediator EGFR 
substrate 15 (EPS15), causing reduced EGFR endocytosis (Fallon et al. 2006). This finding 
provides yet another link between the function Parkinson-associated proteins and receptor 
tyrosine kinases. Parkin was also reported to mediate neuroprotective effects through nuclear 
factor kappa-b (NFκ-B) signaling (Henn et al. 2007).  
 
Parkin knockout mice have been generated by several groups, but as in the case of DJ-1 and also 
PINK1, Parkin knockout mouse have until recently failed to show a loss of dopamine neurons. 
The mice instead display phenotypes related to synaptic transmission and mitochondrial function 
(Goldberg et al. 2003; Palacino et al. 2004; Itier et al. 2003; Perez & Palmiter 2005). In 2011, an 
intriguing study identified a novel target of Parkin, named Parkin interacting substrate (PARIS) 
(Shin et al. 2011). Parkin was found to control PARIS levels by targeting it for proteasomal 
degradation. The authors showed that PARIS represses transcription of PPAR-gamma 
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coactivator-1 alpha (PGC-1α), which in turn regulates expression of another master transcription 
factor, nuclear respiratory factor-1 (NRF-1) – important for mitochondrial function and 
biogenesis. By injecting Cre recombinase-expressing lentiviral vector in the brains of Parkinlx 
mice, Parkin was deleted first in adult mice, and through this knockout strategy, mice lacking 
Parkin showed a striking 40 % loss of dopamine neurons after 6 months. Intriguingly, the 
phenotype was fully rescued with the overexpression of PARIS. Protein levels of PARIS were also 
found to be elevated in brains of PD patients carrying Parkin mutations, as well as in sporadic 
cases. Further studies are required to characterize the Parkin-PARIS pathway in detail and 
investigate the relevance for PD. 
1.2.4. The mitochondrial kinase PINK1 
In 2004, Valente et al mapped the PARK6 locus to the PINK1 gene, and also found somatic 
PINK1 mutations in sporadic disease (Valente, Abou-Sleiman, et al. 2004; Valente, Salvi, et al. 
Figure 1-5 Non-mitochondrial targets of Parkin-mediated ubiquitination. Parkin was shown to decrease EGFR 
endocytosis by inhibiting Eps15, ubiquitinate sp22 alpha-synuclein, reduce ER stress by targeting PAEL-R in a 
complex with CHIP and HSP70, and to label PARIS for degradation, thereby preventing it from inhibiting PGC1-
alpha/Nrf1 transcription, which activate stress response pathways. 
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2004). PINK1 mutations are more common in ARPD than DJ-1 mutations, but are still rare 
(Bonifati et al. 2005). Whether heterozygous PINK1 mutations increase the risk of developing 
sporadic disease has been proposed but is controversial (C. Klein et al. 2007; Bonifati et al. 
2005). PINK1 encodes a serine/threonine kinase with an N-terminal mitochondrial targeting 
sequence and a transmembrane domain (figure 1-4). The PINK1 protein is localized both in the 
cytosol and in mitochondria, where it was found in several different mitochondrial 
compartments, however the details of the localization is a complex and controversial issue 
(Beilina et al. 2005; C. Zhou et al. 2008; Y. Yang et al. 2005; Narendra et al. 2010). To 
understand the various functions of PINK1 (figure 1-6), it is of importance that the protein 
exists in two isoforms, a full length form of approximately 63 kDa and a cleaved form of 
approximately 52 kDa (Beilina et al. 2005). Recently, it was reported by several groups that the 
proteolytic processing of PINK1 is mediated by the protease presenilins-associated rhomboid-like 
protein (PARL), located at the inner mitochondrial membrane (Jin et al. 2010; Deas et al. 2011; 
G. Shi et al. 2011; Meissner et al. 2011). This is also supported by the genetic interaction 
between Pink1 and the Drosophila homolog of PARL, rhomboid-7 (Whitworth et al. n.d.). When 
disrupting the mitochondrial membrane potential, using valinomycin or carbonyl cyanide m-
chlorophenylhydrazone (CCCP), the proteolysis is abolished, stabilizing the full length form, 
which suggests that mitochondrial membrane potential is a key regulator of PINK1 function 
Figure 1-6 Biochemical functions of PINK1. The PINK1 protein exists in a full length 63 kDa form and a 
processed 52 kDa form. Proteolysis of PINK1 is mediated by the protease PARL, after which the cleaved 52 kD
form is degraded by the proteasome. Furthermore, PINK1 was implicated to promote mitochondrial transport on
microtubules in a complex with Miro and Milton. PINK1 was also found to regulate calcium efflux, and to
phosphorylate Trap1, HtraA2 and Parkin. 
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(Silvestri et al. 2005; Narendra et al. 2010; Matsuda et al. 2010). The cleaved form is rapidly 
degraded by the proteasome, which was demonstrated by blocking proteasome activity, leading 
to accumulation of the full length form (Takatori et al. 2008; Gandhi et al. 2009). A model of 
PINK1 activity proposes that in healthy mitochondria, PINK1 is cleaved by PARL at the inner 
membrane, after which the 52 kDa fragment is transported to the proteasome and degraded. 
When mitochondria lose their membrane potential due to impairments, PINK1 can no longer be 
imported through the potential-dependent translocase of outer mitochondrial membrane (TOM) 
complex, hence it cannot be accessed by PARL and instead, it integrates in the outer membrane 
(Jin et al. 2010). This claim that the 52 kDa form is primarily localized at the inner membrane, 
while the full length resides at the outer membrane, was demonstrated in an experiment where 
cells were treated with a proteasomal inhibitor, together with proteinase K, which rapidly 
degraded the 63 kDa form, while the 52 kDa form was protected. This model, on the other 
hand, does not fit well with a report showing cytosolic activity, which used a mitochondrial 
targeting sequence-mutant, but still protected against MPTP toxicity (M Emdadul Haque et al. 
2008). At least three different substrates of PINK1 kinase activity have been reported. One study 
showed that the mitochondrial chaperone tumor necrosis factor receptor-associated protein 1 
(TRAP1) was phosphorylated directly by PINK1, protecting it from cell death by suppressing 
cytochrome-c release (Pridgeon et al. 2007). Another study found that PINK1 phosphorylates 
HtrA2/Omi, a candidate PARK-gene, in response to p38MAPK signaling (Plun-Favreau et al. 
2007). A Drosophila study confirmed a genetic interaction between the PINK1 and HtrA2 in 
vivo (Tain, Chowdhury, et al. 2009). Several reports have shown that PINK1 binds Parkin and 
two controversial reports also showed that Parkin phosphorylation is dependent on PINK1 (Y. 
Kim et al. 2008; Sha et al. 2010), however others found no evidence of phosphorylation 
(Narendra et al. 2010; Vives-Bauza et al. 2010). The significance of the PINK1-Parkin 
interaction is discussed in detail below. Another function of PINK1 is in regulation of 
mitochondrial calcium buffering, as was shown in several studies where mitochondria in PINK1 
deficient cells have elevated calcium levels in neuronal cell lines, cultured neurons, and recently 
in SNpc neurons of PINK1 deficient mice (Marongiu et al. 2009; Gandhi et al. 2009; Akundi et 
al. 2011). Using fluorescent probes specific for cytosolic and mitochondrial calcium, Gandhi et al 
demonstrated that PINK1 activity is specifically required for calcium efflux through the Na+/Ca2+ 
exchanger (Gandhi et al. 2009). In a proteomics study, PINK1 was also implicated in the control 
of mitochondrial transport along microtubules, since the molecular complex of PINK1 and the 
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two kinesin-binding proteins Miro and Milton was found (Weihofen et al. 2009). PINK1 
knockout mice, like Parkin and DJ-1 do not show any neurodegenerative phenotypes, even DJ-
1/Parkin/PINK1 triple mutants have normal numbers of DA neurons (Kitada et al. 2009). 
Instead, PINK1 knockout mice resemble the embryonic Parkin knockouts, with minor 
mitochondrial deficiencies and decreased dopamine release (Kitada et al. 2007; Gautier et al. 
2008; Gispert et al. 2009). In the future, it will be interesting to learn whether adult deletion of 
PINK1 and DJ-1 causes neurodegeneration, as seems to be the case for Parkin. 
1.2.5. Parkin and PINK1 regulate mitochondrial dynamics 
The first evidence for a function of Parkin in regulating mitochondria came in 2003 from 
Drosophila, when Greene et al analyzed a null mutant line for the Drosophila ortholog park, and 
found several phenotypes including severe muscle degeneration, which caused locomotive 
deficiencies and impaired sperm function causing sterility (J. C. Greene et al. 2003). Later, an 
additional small loss of dopamine neurons was reported (Whitworth et al. 2005). All of these 
tissues displayed dramatically enlarged, blob-like mitochondria with broken cristae. A year later, 
mitochondrial dysfunction was also reported in Parkin mutant mice (Palacino et al. 2004). In 
2006, three groundbreaking studies were published simultaneously, which had analyzed Pink1 
mutant or RNAi depleted flies (J. Park et al. 2006; Clark et al. 2006; Y. Yang et al. 2006). 
Intriguingly, Pink1 deficient flies phenocopied park mutants, and when Parkin was overexpressed 
in Pink1 mutants, the phenotypes were fully rescued, but interestingly PINK1 overexpression did 
not rescue the Pink1 mutant phenotypes. These two observations suggest that Parkin and PINK1 
act in a common pathway regulating mitochondria, critical for the integrity of the phenotypic 
tissues, with PINK1 upstream of Parkin. A year later it was shown in HeLa cells that PINK1 
knockdown causes mitochondrial fragmentation, which could be rescued by Parkin 
overexpression (Exner et al. 2007).  
 
In many cell types, mitochondria appear as long tubules, interconnected in a dynamic network 
together with small round structures (D. C. Chan 2006; Westermann 2010). The morphology of 
the network is highly regulated by fusion and fission events, controlled by specific proteins. In 
mammals, mitofusins 1/2 (Mfn1/2) mediate outer membrane fusion, and optic atrophy 1 
(Opa1) mediates inner membrane fusion, while the cytosolic dynamin related protein 1 (Drp1) 
together with mitochondrial fission 1 (Fis1) mediate fission. For many reasons, fusion and fission 
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are critical for maintaining a healthy pool of mitochondria, but fission also appears to be 
connected with apoptosis (Der-Fen Suen et al. 2008). In park and Pink1 mutant Drosophila, the 
mitochondria appeared blob-like, indicating that the balance is shifted towards fusion, and 
indeed, decreasing fusion or increasing fission rescues the phenotypes (Poole et al. 2008; Deng et 
al. 2008; J. Park et al. 2009). In contrast, in mammalian cells where Parkin or PINK1 were 
acutely depleted, or in fibroblasts from PINK1-PD patients, the mitochondria appeared 
fragmented, indicating increased fission (Exner et al. 2007; Dagda et al. 2009; Lutz et al. 2009). 
Indeed, it was later shown that depleting Drp1 or overexpressing Opa1 could rescue 
mitochondrial phenotypes from Parkin or PINK1 depletion in SH-SY5Y cells, and conversely 
PINK1 or Parkin overexpression could rescue fragmentation from Drp1 overexpression (Lutz et 
al. 2009). The differences between the results from Drosophila and cultured mammalian cells are 
unlikely to be due to a complete switch of function of Parkin and PINK1 between the species. A 
more likely explanation is that Parkin and PINK1 control mitochondrial dynamics via an 
indirect mechanism, where Parkin or PINK1 deficiencies cause a basic mitochondrial 
dysfunction that is handled differently in the two systems.  
1.2.6. A PINK1-Parkin pathway initiates mitophagy 
Further insight into how Parkin and PINK1 might function in mitochondria came when it was 
shown that the normally cytosolic Parkin is recruited to mitochondria with decreased membrane 
potential by binding to PINK1, and promotes their degradation through mitophagy, the 
autophagy of mitochondria (Matsuda et al. 2010; Narendra et al. 2010; Vives-Bauza et al. 2010) 
(figure 1-7). One study reported that Parkin controls this process by ubiquitinating the voltage 
dependent anion channel 1 (VDAC1) (Geisler et al. 2010), whereas three other studies showed 
that Parkin ubiquitinates Mfn1/2 and proposed that this initiates mitophagy (Gegg et al. 2010; 
Ziviani et al. 2010; Poole et al. 2010). However, Tanaka et al showed that even though Parkin 
ubiquitinates Mfn1/2, Parkin-dependent mitophagy also occurred in Mfn1-/-/Mfn2-/- mouse 
embryonic fibroblasts (MEFs). The function of mitophagy is believed to be clearing the cell of 
damaged mitochondria (Youle & Narendra 2011). How does the PINK1-Parkin mitophagy 
pathway fit with the studies showing a regulatory effect on fusion or fission? The question 
remains unanswered, but it is possible to speculate on different scenarios. For example, damaged 
mitochondria might undergo increased fission, as in the well known fragmentation upon 
oxidative stress or prior to cytochrome-c release (Der-Fen Suen et al. 2008). When blocking the 
Introduction 33 
autophagic pathway by removing PINK1 or Parkin function, the mitochondrial fragments would 
accumulate, giving a fragmented morphology in the cell, without directly regulating fusion or 
fission. On the other hand, Parkin-mediated ubiquitination of mitofusins may simply target 
them for degradation, causing a shift in the balance towards fusion, as argued by Tanaka et al (A. 
Tanaka et al. 2010). The mitophagic pathway provides a cell biological and biochemical 
explanation for the genetic link between PINK1 and Parkin in Drosophila, and disruption of this 
pathway may be a step towards PD pathology. The model is somewhat inconsistent concerning 
the requirement of PINK1 in recruiting Parkin to the mitochondria, considering the fact that 
Parkin overexpression rescues the phenotypes of Pink1 mutant Drosophila, without Pink1 being 
present for the recruitment. Most of the studies concerning the mitophagy pathway discussed 
above were performed in HeLa or similar cell lines, and interestingly a study using cultured 
Figure 1-7 Model of the PINK1-Parkin pathway of mitochondrial quality control and initiation of mitophagy. In
healthy mitochondria, PINK1 is maintained at low levels, as it is cleaved at the inner membrane by PARL, causing
proteasomal degradation. When mitochondria are impaired and lose membrane potential, PINK1 is no longer
imported to the inner mitochondrial membrane, instead it integrates in the outer membrane. There, PINK1, 
recruits Parkin, which ubiquitinates mitochondrial proteins such as Mfn1/2 and VDAC, and this initiates a 
mitophagic pathway leading to degradation of impaired mitochondria. 
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neurons failed to see Parkin translocation to depolarized mitochondria, due to their different 
bioenergetic properties (Van Laar et al. 2011). Also, it cannot be ruled out that loss of other 
functions of PINK1 and Parkin cause independent mitochondrial impairments – for PINK1 in 
regulating TRAP1, HtrA2 and calcium efflux, and for Parkin in regulating mitochondrial 
transport or the recently indentified PARIS transcription factor. The fact that PINK1 
knockdown in HeLa cells, which due to oncogenic mutations in the cell line lack a functional 
Parkin gene (Denison et al. 2003), still causes robust mitochondrial fragmentation (Exner et al. 
2007), also suggests that independent functions of PINK1 and Parkin control mitochondrial 
integrity. Further studies are required to clarify the link between mitophagy and mitochondrial 
dynamics, to explain the differences between the studies of Drosophila and mammalian cell lines, 
and to show the significance for Parkinson’s disease. 
1.3. GDNF/Ret signaling and its function in dopamine neurons 
1.3.1. Overview of neurotrophic factors and their receptors 
Figure 1-8 GDNF family of ligands bind to GDNF family receptor alpha’s. GDNF binds primarily to GFRα1, 
and with low affinity to GFRα2 and GFRα4. Neurturin (NRTN), binds primarily to GFRα2, and with low affinity 
to GFRα1 and GFRα3, while Artemin (ARTN) binds primarily to GFRα3, and with low affinity to GFRα2 and 
GFRα4. Persephin (PSPN) on the other hand, binds selectivily to GFRα4 
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Neurotrophic factors are secreted proteins that can promote the survival, development and 
plasticity of neurons. The original neurotrophic theory postulates that during development of the 
nervous system, neurons are formed in excess but are dependent on neurotrophic factors for their 
survival. These factors are secreted by the target tissues and taken up by the terminals of the 
growing axons. Neurons that extend their axons to the correct target will survive, while neurons 
that do not find the sources of target-derived neurotrophic factors are eliminated. Such a system 
allows a target tissue to regulate its innervation by eliminating both excess of innervation and 
misprojecting fibers. The neurotrophic factors can be grouped into four families, the first being 
the neurotrophins, comprised of nerve growth factor (NGF) and the structurally related brain-
derived neurotrophic factor (BDNF), neurotrophin 3 and neurotrophin 4/5. A second family is 
the GDNF family of ligands (GFLs), distantly related to the TGF-ß superfamily, which in 
addition to GDNF contains its three paralogs artemin (ARTN), neurturin (NRTN), and 
persephin (PSPN). The third family of neurotrophic factors is the neuropoietic cytokines, and 
Figure 1-9 Model of GDNF signaling via GFRα1 and Ret. The secreted GDNF protein forms a native 
homodimer, which binds to a dimer of GPI linked GFRα1 on the cell surface. Upon GDNF binding, GFRα1 can 
bind to a dimer of the transmembrane receptor tyrosine kinase Ret, which causes trans-autophosphorylation of the 
intracellular kinase domains and subsequent activation of intracellular signaling cascades. Whether Ret is
predimerized at an inactive state prior to GDNF/GFRα1 binding, or whether it dimerizes upon binding is unclear. 
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the fourth family is formed by the recently discovered cerebral dopamine neurotrophic factor 
(CDNF) and mesencephalic astrocyte-derived neurotrophic factor (MANF). Currently, many 
other functions of neurotrophic factors have been discovered, outside the scope of the original 
neurotrophic theory, such as regulation of migration, neurite branching, synaptogenesis, and 
synaptic plasticity (A. M. Davies 1996).  
1.3.2. The GDNF family of ligands signal via GFRαs,  -Ret, and NCAM 
Each of the GFLs binds to a GDNF family receptor alpha 1-4 (GFRα-14) (figure 1-8) in a 
homodimeric state. GDNF itself binds primarily to GFRα1, although some promiscuity exists 
(Airaksinen & Saarma 2002). The GFRαs cannot transduce signaling to the cell by themselves as 
they lack an intracellular domain, instead they bind to the plasma membrane with a 
glycosylphosphatidylinositol (GPI) anchor and function as co-receptors. Two receptors for the 
GFRα/GFL complexes have been found: The first identified was rearranged during transfection 
(Ret), belonging to the receptor tyrosine kinase family of receptors (Durbec et al. 1996; Trupp et 
al. 1996). Later, it was found that the neural cell adhesion molecule (NCAM) can serve as a 
receptor for GDNF/GFRα1 (Paratcha et al. 2003). GDNF signaling via NCAM activates focal 
adhesion kinase (FAK) and Fyn kinase, which function in neuronal migration. GDNF signaling 
via NCAM was also found to act as a chemoattractant for cells in the rostral migratory stream 
(Paratcha & Ledda 2008). According to the established model of Ret signaling, Ret does not 
bind to GFRα alone, but rather to the GFL/GFRα complex, after which Ret undergoes 
dimerization and trans-autophosphorylation of the intracellular tyrosine kinase domains (figure 
1-9) (Schlee et al. 2006). However, it has also been proposed that Ret undergoes predimerization 
prior to GFL/GFRα binding, but does not turn catalytically active until the GFL binds (Knowles 
et al. 2006).  
1.3.3. Ret is evolutionary conserved in vertebrates and Drosophila 
Ret is evolutionary conserved in all vertebrates examined from human to zebrafish (Airaksinen et 
al. 2006). Also, Drosophila has a clear Ret homolog, Dret, and in addition another possibly 
related gene, the recently cloned stitcher (S. Wang et al. 2009). Orthologs of the four GFRα’s 
have been identified in all examined vertebrates, but not all four of the GFLs appear to be 
conserved, suggesting a certain redundancy in the system. Drosophila has a homolog of the 
GFRαs called GFR-like, but to date no Drosophila homologs of the GFLs have been described. 
Interestingly, Dret was overexpressed in cell culture and could activate many of the same 
Introduction 37 
pathways as mammalian Ret (Abrescia et al. 2005) and expression analysis studies have shown 
that Dret is expressed in many analogous tissues to human Ret, such as in neuroendocrine cells, 
peripheral neurons, and the ventral nerve cord during development, suggesting a conserved 
function (Sugaya et al. 1994; Hahn & Bishop 2001; Fung et al. 2008).  
1.3.4. Ret domain structure and tyrosine kinase signaling 
The human Ret transcript is spliced into three isoforms, expressing proteins with different 
lengths of the carboxy-terminal cytoplasmic tail: Ret9, Ret43 and Ret51, representing the 
number of amino acids in the tail domain. However Ret43 is not as evolutionarily conserved as 
the others, and also not as well studied (figure 1-10). The extracellular domain of Ret contains 
four cadherin-like domains, and a cysteine-rich domain. The intracellular domain contains a 
juxtamembrane domain, and a tyrosine kinase domain with 16-18 tyrosines residues, out of 
which six have been implicated to be involved in signaling. In addition, the long isoform Ret51 
has the additional Y1096 not not present in the cytoplasmic tails of the shorter isoforms. When 
phosphorylated, these tyrosines can recruit a large number of adaptor proteins (figure 1-11): 
Y752 and Y928 bind signal transducer and activator of transcription 3 (STAT3), Y905 binds 
growth factor-bound protein 7/10 (Grb7/10) (Pandey et al. 1996), Y981 binds Src and Y1015 
Figure 1-10 Domain structure of mammalian Ret. The Ret protein contains an extracellular domain with four
cadherin-like domains and a cystein-rich domain. A transmembrane domain spans the plasma membrane, and the
intracellular domain, in turn, contains a juxtamembrane domain, a tyrosine kinase domain, and a cytoplasmic tail.
Ret is found in three splice isoforms with different lengths of the cytoplasmic tail, Ret9, Ret43, and Ret51. 
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binds phospholipase C-gamma (PLC γ) (Schuringa et al. 2001; Pandey et al. 1996; Mario 
Encinas et al. 2004; Borrello et al. 1996). Of particular importance is Y1062, which acts as a 
binding site for a variety of adaptors and thereby, is responsible for the activation of several 
different signaling pathways (Hayashi et al. 2000). Binding of Fibroblast growth factor receptor 
substrate 2 (Frs2) causes activation of Ras-Erk signaling, either in a transient manner via Grb2 
and son of sevenless (SOS), or alternatively by binding to Src homology domain-containing 
phosphatase 2 (Shp2), which leads to a more sustained activation (Hayashi et al. 2000; Kurokawa 
et al. 2001). In addition, docking protein (Dok) 4/5 binding to Y1062 together with SOS also 
activates Ras. Dok1 binding to Y1062, on the other hand, was reported to active c-jun N-
terminal kinase (JNK) signaling (Hayashi et al. 2000). Y1062 also mediates phosphoinositide-3-
kinase (PI3K) signaling via recruitment of the Src homology domain-containing 
(Shc)/Grb2/Grb-associated-binding protein 1 (Gab1) complex, or via insulin receptor substrate 
(IRS) binding (Besset et al. 2000; R M Melillo et al. 2001). In addition, Y1062 has been shown 
to be critical for activation of ERK5 and p38MAPK signaling through an unknown mechanism 
Figure 1-11 Phosphotyrosines of the kinase domain recruit adaptor proteins and initiate signal transduction. The 
kinase domain of mammalian Ret contains six signaling tyrosines, and in addition, the long isoform Ret51, contains 
the additional Y1095. The signaling tyrosines recruit a number of adaptor protein complexes, which leads to the 
activation Ras, PI3K, JNK, p38MAPK, Erk5, PLCγ, STAT3, Src, and their downstream signaling pathways.
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(Drosten & Pützer 2006; Kodama et al. 2005). The last signaling tyrosine, Y1092 which is only 
present in the long Ret51 isoform, binds to Grb2, but only mediates activation of PI3K via a 
Gab2/Shp2 complex (Besset et al. 2000).  
1.3.5. Functions of Ret in development 
Ret has important functions during development and is expressed in the kidney, the enteric 
nervous system (ENS), testis, cranial ganglia, motor neurons in the spinal cord, and midbrain. 
GDNF/Ret signaling appears to be particularly critical for kidney and ENS morphogenesis, as 
mice lacking either Ret, GFRα1 or GDNF die soon after birth due to severe kidney dysfunction 
and intestinal aganglionosis (Schuchardt et al. 1994; M. W. Moore et al. 1996; Pichel et al. 
1996; Sánchez et al. 1996; Enomoto et al. 1998; Cacalano et al. 1998). In the developing kidney, 
GDNF is secreted by the nephrogenic mesenchyme, whereas Ret is expressed in the tips of the 
uretic buds. By secreting GDNF, the mesenchyme can induce bud-branching (Hellmich et al. 
1996; Sainio et al. 1997). Another example of how GDNF/Ret signaling functions in 
development, is during spermatogenesis, where Sertoli cells secrete GDNF, which is received by 
Ret in undifferentiated spermatogonia (Meng et al. 2000). Mice heterozygous for GDNF have 
lower numbers of spermatogenic stem cells, whereas mice overexpressing GDNF show increased 
numbers of undifferentiated spermatogonia (Viglietto et al. 2000). Together these data suggest 
that GDNF promotes self-renewal of spermatogonia, in favour of differentiation. A third 
developmental function of GDNF/Ret signaling is to promote growth of motor neurons during 
hind limb development. At the choice point of dorsal or ventral innervation, axons in GDNF or 
Ret null mice were shown to choose a ventral trajectory to a higher extent than in controls, as 
GDNF act as a chemoattractant (Kramer et al. 2006; Dudanova et al. 2010). Interestingly the 
two main isoforms of Ret, Ret9 and Ret51 are differentially expressed in some tissues and are 
believed to have somewhat different functions. In a study by Graaf et al, monoisoformic mice 
were generated, and the mice lacking the Ret9 isoform showed a similar phenotype to null mice, 
whereas mice lacking Ret51 only showed minor phenotypes (de Graaff et al. 2001). These results 
were, however, contradicted by another study where both Ret9 and Ret51 monoisoformic mice 
developed normally, suggesting that they compensate for each other (Jain, Mario Encinas, et al. 
2006). 
1.3.6. Ret signaling in disease 
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Ret was originally identified in a transformation assay with DNA from a T-cell lymphoma, and 
has been implicated in several diseases. Ret gain-of-function mutations are the primary cause of 
multiple endocrine neoplasia type 2 (MEN2), a syndrome characterized by medullary thyroid 
carcinoma (MTC), together with other symptoms. Depending on which other symptoms 
accompany the carcinoma, MEN2 can be subdivided in MEN2A, MEN2B and FMTC (familial 
MTC). Interestingly, patients with MEN2A typically have mutations in one of six cysteines in 
the cysteine-rich domain, causing dimerization through the formation of abnormal covalent 
disulphide bridges and subsequent autoactivation of the receptor (figure 1-12) (Massimo Santoro 
et al. 2002). MEN2B patients, on the other hand, typically have mutations in the intracellular 
kinase domain; around 95 % of the cases are specifically caused by the M918T mutation (figure 
1-13). These mutations are thought to cause a conformational change of the kinase domain, 
generating autoactivation either as a monomer or a dimer (R. M. Hofstra et al. 1994). Patients 
with MEN2B mutations are also reported to have increased autophosporylation of Y1062 (D. 
Salvatore et al. 2001), leading to a shift in substrate specificity. FMTC patients do not show any 
additional symptoms, and may have mutations either in the cysteine-rich domain or in the kinase 
domain. To date, it is not clear why the different types of mutations cause different symptoms in 
Figure 1-12 Activating mutations in Ret cause multiple endocrine neoplasia type 2. The majority of mutations 
causing MEN2A are located in the cysteine-rich domain, creating abnormal disulphide bridges, leading to 
dimerization and constitutively active signaling. Conversely, most MEN2B-causing mutations are located in the
kinase domain, generating a conformational change, also leading to constitutive activity, either as a monomer or 
dimer. 
RetMEN2A
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RetMEN2B
M918T
A883F
C609
C611
C618
C620
C630
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MEN2A and MEN2B patients. Mutations in Ret can also cause Hirschprung’s disease (HSCR), 
characterized by a lack of the distal segments of the enteric nervous system. HSCR mutations are 
scattered all over the Ret gene, some of them in the kinase domain were studied in detail and 
were found to cause kinase inactive receptors (Francesca Carlomagno et al. 1996), suggesting that 
HSCR is a Ret loss-of-function disease. 
1.3.7. GDNF/Ret signaling protects dopamine neurons from toxins and promotes resprouting 
GDNF was first isolated from primary ventral midbrain cultures in 1993 for its ability to 
promote survival of cultured dopamine neurons (L. F. Lin et al. 1993). When supplying 
recombinant GDNF to the cultures at a low concentration of 1 ng/ml over three weeks, it tripled 
the survival specifically of DA neurons. After this initial discovery, it did not take long until other 
researchers reported that GDNF infusion protects dopamine neurons in mice from MPTP or 6-
hydroxy-dopamine (6-OHDA) lesions (Tomac et al. 1995) and soon thereafter, the same effect 
was reported in primates (Gash et al. 1996). Two early clinical trials showed positive results with 
improvements of motor functions in patients that were delivered GDNF by intracranial infusion 
(Gill et al. 2003; Slevin et al. 2005), but a larger phase II trial unfortunately did not show the 
same positive results and had to be cancelled prematurely (Lang et al. 2006). However, there is a 
large ongoing clinical development of GDNF and other GFL-based therapies for PD using viral 
vectors and other delivery systems (Kordower et al. 2000). There is also an ongoing effort to 
develop small molecule GDNF mimetics that could allow more efficient delivery (Bespalov & 
Saarma 2007). 
1.3.8. Physiological function of GDNF/Ret in survival of dopamine neurons  
The studies described above have collectively shown that supplying exogenous GDNF to various 
systems can protect against dopamine cell death, and promote resprouting of axonal fibers after 
lesions. However, after 18 years of GDNF-signaling research, our understanding of its 
physiological function in dopamine neurons is still very limited. GDNF is expressed in several 
areas of the adult mammalian brain, with the highest levels are found in the striatum, cerebellum, 
olfactory bulb and hippocampus. The origin of striatal GDNF is debated, but it has been 
suggested that it is secreted by GABAergic and cholinergic interneurons (Bizon et al. 1999). Ret 
and GFRα1 are expressed on the terminals of dopaminergic striatal axons, but also in cell bodies 
in the midbrain. Mice overexpressing a constitutively active version of Ret, analogous to human 
RetMEN2B mutations, showed an increased number of DA neurons in the SNpc (Mijatovic et al. 
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2007). Surprisingly however, knockout mouse models of GDNF, GFRα1or Ret, even though 
they die soon after birth, develop with a normal complement of DA neurons, suggesting that 
GDNF-Ret signaling does not play an important role in DA neuron development (M. W. 
Moore et al. 1996; Enomoto et al. 1998; Schuchardt et al. 1994). In a recent study, mice with a 
floxed Ret allele, recombined at early embryonic stages using either a dopamine neuron specific 
Cre line (DAT) or a pan-neuronal Cre line (nestin), were followed until 24 months of age. At 9 
months, a small decrease in the density of striatal DA fibers was seen, and at 12 months there was 
a significant loss of TH+ neurons in the SNpc. At 24 months, the decrease of TH+ striatal fibers 
had reached 60 %, and the loss of TH+ SNpc neurons had reached 38% (Kramer et al. 2007). 
These results were however not supported by another study where no neurodegeneration was 
observed up to 12 months, although it is possible that by pooling mice between 6 and 12 
months, a milder phenotype may have been obscured (Jain, Golden, et al. 2006).  
 
Another recent study investigated the physiological role of GDNF in dopamine neurons by 
ablating GDNF in the brains of two month old mice using a floxed GDNF allele and a 
tamoxifen-inducible Cre line. These mice underwent a dramatic degeneration - at seven months 
they showed a loss of 60-70 % of TH+ neurons in SNpc, and the noradrenergic neurons in the 
coeruleus locus were almost absent. However, the authors used an unusually high dosage of 
tamoxifen, and it is possible that the effects may partially be due to toxicity of this drug, since 
Ret signaling was shown to protect against tamoxifen toxicity (Plaza-Menacho et al. 2010). Still, 
it opens up the question of whether the significantly stronger phenotype of the GDNF knockout 
than of that of the Ret knockout is due to the presence of alternative GDNF receptors, or 
whether it is an effect of adult deletion, circumventing potential mechanisms that might 
compensate for an embryonic loss of function. No pro-survival function of NCAM has been 
reported for DA neurons, but it is worth considering NCAM as such an alternative. Further 
studies that delete Ret and GDNF using the same method are required to better characterize the 
difference of ablating the two genes.  
1.3.9. Mechanism of GDNF/Ret mediated neuroprotection remains unclear 
The studies deleting GDNF or Ret in mice have shown that Ret has a physiological function in 
promoting the survival of dopamine neurons during aging. It remains largely unclear, however, 
what underlying mechanism that protects against cell death in these aging cells on a 
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cellbiological/biochemical level, and importantly how it functions. In cultured neurons or 
neuronal cell lines, Ret has been shown to activate the PI3K/Akt, Ras/Erk, PLCγ, JNK, 
p38MAPK, and Src kinase signaling pathways (Kurokawa et al. 2003). The PI3K/Akt pathway in 
particular, has been shown several times to be highly important for neuronal survival and is 
activated by GDNF (Dudek et al. 1997; Ries et al. 2006; Neff et al. 2002), however, the role of 
the Akt pathway in the specific context of Ret signaling during aging has not been investigated. 
Even less certain is which critical cellular functions such a pathway helps to maintain, to be able 
to protect against dopamine neuron degeneration. In a study using cultured sympathetic neurons 
from knockin mice with different signaling mutant versions of Ret, it was found that sympathetic 
neuron survival is independent of Akt, but instead relies on a B-Raf/inhibitor of kappa-B kinase 
(IKK) pathway (M Encinas et al. 2008). It was also recently reported that GDNF overexpression 
in the striatum of rats caused an upregulation of TH and delta-like 1 homolog (Dlk1), a 
transcription factor involved in proliferation, in the SN but the mechanism of upregulation is 
unclear (Christophersen et al. 2007). Now that it is known that GDNF/Ret signaling has an 
important function for the survival of aging nigrostriatal neurons, future studies are required to 
elucidate the nature of this function. 
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1.4. Purpose of thesis project 
In this project I sought to gain new insight into the mechanisms by which GDNF/Ret signaling 
promotes the survival of midbrain dopamine neurons during aging. Novel information in this 
field would contribute to our general understanding of the functions of neurotrophic factors in 
adults, and in particular, it would help answer the important question of why dopamine neurons 
need GDNF. 
 
During the past decade, familial forms of Parkinson’s disease have been mapped and the 
functions of the associated proteins are rapidly being elucidated by scientists worldwide. These 
novel functions led us to hypothesize that Ret signaling cooperates with the ARPD-associated 
proteins in maintaining certain cellular functions that are specifically critical for SNpc dopamine 
neuron survival. Such cellular functions may include signal transduction pathways, 
transcriptional regulation, and mitochondrial integrity. This hypothesis would explain why 
GDNF and Ret mutant mice develop parkinsonism like phenotypes, it would also provide an 
important mechanism of action for a potential future Parkinson’s disease therapeutics. In 
addition, exploring this theory may provide new insight into the physiological functions of 
ARPD-associated proteins. 
 
To test the hypothesis, I asked the following specific questions: 
 
i. Is combined Ret and DJ-1 activity critical for the survival of dopamine neurons in aging 
mice? 
ii. Do Ret and DJ-1 target a common signal transduction pathway? 
iii. Can Ret signaling reverse mitochondrial impairments caused by Parkin or PINK1 
depletion in vitro? 
iv. Can Ret signaling complement park or Pink1 loss-of-function in Drosophila? 
v. Is combined Ret/Parkin and/or Ret/PINK1 activity critical for the survival of dopamine 
neurons in aging mice? 
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2. Results 
2.1. Genetic interaction between Ret and DJ-1 in maintenance of 
nigrostriatal dopamine neurons during aging in mice  
2.1.1. Combined activity of Ret and DJ-1 required for the survival of midbrain dopamine neurons 
in aging mice 
Dopaminergic conditional Ret knockout mice, (DAT-Cre;Retlx/lx), hereafter named “Ret”, have 
previously been reported by our group to develop a progressive, mild and highly age dependent 
loss of dopaminergic neurons in the SNpc, together with a larger loss of dopaminergic axonal 
fibers in the striatum – a phenotype that in many aspects resembles Parkinson’s disease. 
Knockout models of the mouse homolog of the ARPD-causing gene DJ-1 however, do not show 
neurodegenerative phenotypes, only mild synaptic defects, but importantly no loss of nigral 
neurons (R. H. Kim, P. D. Smith, et al. 2005; Goldberg et al. 2005; Linan Chen et al. 2005; 
Chandran et al. 2008; Yamaguchi & J. Shen 2007). Thus, we hypothesized that Ret signaling 
interacts genetically with DJ-1, and we wanted to test whether mice lacking both Ret and DJ-1 
undergo increased neurodegeneration. For this purpose, Ret mice were crossed with mice 
carrying a DJ-1 null allele (“DJ-1”) (T.-T. Pham et al. 2010), resulting in mice that lack Ret 
specifically in dopaminergic cells and DJ-1 in all cells. In addition to being active in 
dopaminergic cells, the DAT-Cre recombinase is also expressed in the germ line, hence when 
crossing DAT-Cre;Retlx to the DJ-1 allele, Ret was frequently recombined in all cells, generating 
lx/null heterozygous mice, which is the final genotype that was analyzed. 
2.1.2. Increased loss of substantia nigra neurons in mice lacking both Ret and DJ-1 
DAT-Cre;Retlx/-;DJ-1-/- (Ret/DJ-1) double mutant mice, together with DJ-1 and Ret single 
mutants and mixed littermate controls were analyzed at 3, 18, and 24 months of age. 
Stereological quantifications of dopamine neurons of the ventral midbrain were performed in 
coronal brain sections immunostained for the dopamine neuron marker tyrosine hydroxylase 
(TH). At 3 months, the number of dopamine neurons in Ret/DJ-1 double mutant mice remained 
unchanged as compared to control mice, in both the SNpc and in the VTA (data not shown). At 
18 months, DJ-1 mutant mice showed no significant loss of neurons in the SNpc, in agreement 
with previous reports (figure 2-1a,c). Ret mice showed a 24% reduction of TH+ neurons in the 
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Figure 2-1 Combined activity of Ret and DJ-1 is required for the survival of dopamine neurons in aged mice. (a-b)
Photomicrographs of coronal brain sections from 18 month old control, DJ-1, Ret, and Ret/DJ-1, DAT-Cre and
DAT-Cre/DJ-1 mutant mice showing dopamine neurons in the substantia nigra (SNpc) and the ventral tegmental
area (VTA) stained for the DA markers TH (a) and Pitx3 (b). (c-h) Stereological quantifications of DA neurons: (c) 
TH+ SNpc neurons at 18 months, (d) TH+ VTA neurons at 18 months, (e) TH+ SNpc neurons at 24 months, (f)
Pitx3+ SNpc neurons at 18 months, (g) NeuN+ SNpc neurons at 18-24 months, (h) TH+ SNpc neurons at 18 
months. n=5 mice per genotype, means ± SEM, * p<0.05, ** p<0.01, *** p<0.001, Student’s t-test. n.s. = not 
significant. Scale bars: (a) 250 μm, (b) 50 μm. Complete genotypes: mixed controls, DJ-1-/-, DAT-Cre;Retlx/-, DAT-
Cre;Retlx/-;DJ-1-/-, DAT-Cre, DAT-Cre;DJ-1-/-. Mice were bred by Liviu Aron, perfusions and histological preparations 
were performed by L. Aron and P. Klein, immunostainings were performed by L. Aron, stereological quantifications
in (c),(e),(f),(g),(h) were performed by L. Aron, (d) and (f) by P. Klein. 
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SNpc as compared to controls, while Ret/DJ-1 double mutant mice showed a reduction of 37%, 
indicating that combined loss of DJ-1 and Ret in SNpc neurons caused increased 
neurodegeneration. There was no reduction in the number of neurons in the VTA indicating an 
intrinsic difference in sensitivity to Ret/DJ-1 loss-of-function between the two neuronal 
populations (figure 2-1d). In 24 month old mice, the loss of TH+ neurons in the SNpc remained 
similar to that of 18 month (25%), while Ret/DJ-1 double mutants displayed a 41% reduction 
compared to controls - a further reduction in double mutants compared to Ret single mutants 
with increasing age. To verify that the reduced quantified number of neurons was not due to 
decreased expression of TH, sections were also stained for another dopaminergic marker, Pitx3 
and counted, with similar results (2-1b,f). Also the pan-neuronal marker neuronal nuclei (NeuN) 
indicated a loss of total neurons in the SNpc area (figure 2-1g). To control for a genetic 
interaction between DJ-1 and the DAT-Cre line, TH+ neurons in DJ-1/DAT-Cre mice were 
quantified at 18 months, but no loss of neurons was observed as compared to control or DAT-
Cre (2-1h). Therefore, the possibility that the loss of neurons was due to an interaction between 
DJ-1 and the DAT-Cre line could be excluded. 
2.1.3. No further loss of striatal dopaminergic fibers in double mutant mice 
It has previously been shown that Ret mice lose a substantial amount of fibers in the striatum, 
reaching approximately 40% at 12 months and 63% at 24 months (Kramer et al. 2007) − 
numbers that highly exceed the loss of TH+ SNpc cell bodies at the same time points. To assess 
whether Ret/DJ-1 double mutant mice lose additional fibers, coronal brain sections from 18 and 
24 month old mice were immunostained for two independent dopaminergic markers, TH and 
DAT, (experiments performed by L. Aron). Fiber density in the dorsal striatum was quantified 
using an automated counting grid-based algorithm on thresholded images. The analysis showed 
that aged Ret mutant mice had lost approximately 33% of the TH+ fibers at 18 months and 52 
% at 24 months, and 54% of the DAT+ fibers at 24 months compared to controls (data not 
shown). Interestingly, there was no significant further reduction of fibers in the Ret/DJ-1 double 
mutant mice, indicating that DJ-1 is only required for promoting the survival of the dopamine 
neurons, but not for maintaining their target innervation. 
2.1.4. Increased locomotion and striatal dopamine in DAT-Cre mice – no reduction in Ret/DJ-1 
double mutants 
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Behavioral symptoms in PD as well as in mouse models typically appear when more than 60-70 
% of the SNpc neurons are lost. On the other hand, behavioral alterations in PD models may 
appear without an accompanying loss of neurons being due solely to impaired synaptic function. 
In order to examine whether the Ret/DJ-1 double mutant mice show any differences in overall 
locomotion, 18-24 month old mice were subjected to behavioral assessments, where movements 
were tracked during 20 minutes in an open field arena (figure 2-2a). The results indicated that 
DJ-1 mutant mice had reduced locomotion as compared to controls, in agreement with previous 
reports (Goldberg et al. 2005; Chandran et al. 2008; Yamaguchi & J. Shen 2007). Mice carrying 
the DAT-Cre allele showed increased activity, also reported previously, and likely explained by 
Figure 2-2 Increased behavior and striatal dopamine in DAT-Cre mice, no reduction in Ret/DJ-1 mutants. (a-c) 
Extended analyses of 18-24 month old control, DJ-1, Ret, and Ret/DJ-1, DAT-Cre mice. (a) Behavioral assessment of 
18-24 month old mice in an open-field arena where horizontal movement was automatically tracked during 20 min,
n=7-16 mice per genotype, (b) HPLC measurement of total striatal dopamine content of 18 month old mice, n=5-7
mice per genotype, (c) representative western blot of striatal lysate from 24 month old mice, anti-TH and beta-actin
antibodies as indicated (d). Optical density measurement of 3 western blots from (c) n=5-8 mice per genotype, 
means ± SEM, * p<0.05, ** p<0.01, one-way ANOVA with Bonferroni’s post-hoc test. Complete genotypes: mixed 
controls, DJ-1-/-, DAT-Cre;Retlx/-, DAT-Cre;Retlx/-;DJ-1-/-, DAT-Cre. Behavior experiment (a) was performed by L. 
Aron and P. Klein. HPLC samples were prepared by P. Klein, HPLC was performed by Birgitte Nuscher (LMU, 
Munich). 
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the reduced expression of the dopamine transporter, which decreases dopamine reuptake in the 
striatum. The Ret mice, as well as Ret/DJ-1 double mutant mice showed the same increase in 
locomotion as compared to controls, but no difference when compared to DAT-Cre alone. The 
results indicate that the amount of neurodegeneration is not significant enough to cause 
behavioral impairments, but it is still possible that effects are masked to some extent by the 
hyperactivity caused by the DAT-Cre allele. Measurements of total striatal dopamine content 
from mice of the same age were performed using high-performance liquid chromatography 
(HPLC) (figure 2-2b). The results showed significantly elevated dopamine levels in DAT-Cre, 
Ret, and Ret/DJ-1 mice as compared to controls. Interestingly, there was no difference between 
DAT-Cre and Ret and Ret/DJ-1 mice, which suggests that dopamine levels may be upregulated in 
the Ret and Ret/DJ-1 mutant mice, considering that the density of striatal fibers at the same time 
point was significantly decreased compared to controls. In order to test whether TH levels, the 
rate-limiting enzyme in the dopamine synthesis pathway, were altered TH protein levels were 
measured by western blot analysis (figure 2-2c,d). However due to a limited availability of 18 
month old mice, brains from 24 month old mice were used instead. Results did not indicate an 
upregulation of TH, although it cannot be excluded that the levels were again downregulated at 
the later 24 month stage.  
Figure 2-3 Smaller cell bodies of SNpc dopamine neurons in Ret mice – no increase in Ret/DJ-1 double mutants. 
(a) Photomicrograph of coronal brain sections from control or Ret mice, immunostained for the DA marker GIRK2,
with cell bodies outlined, scale bar=50 μm (b) Percentage of GIRK2+ SNpc cell bodies with areas <150 μm2, 150-
250 μm, or >250 μm2 from control, DJ-1, Ret or Ret/DJ-1 mutant mice. n=149-274 cells per animal, 5-7 animals 
per genotype, means ± SEM, * p<0.05, one-way ANOVA, Bonferroni’s post-hoc test. Complete genotypes: mixed 
controls, DJ-1-/-, DAT-Cre;Retlx/-, DAT-Cre;Retlx/-;DJ-1-/-. 
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2.1.5. Reduced cell soma size in Ret mutant mice, but no significant difference in Ret/DJ-1 double 
mutants 
Aged Ret single mutant mice display a loss of approximately 50 % of the dopaminergic axons in 
the striatum, but only 25 % of the dopaminergic cell bodies in the SNpc. Ret/DJ-1 double 
mutants displayed a larger loss of cell bodies, but no increased loss of striatal fibers. One 
hypothesis that could explain these findings is that in the Ret mice, there is a population of 
neurons that have lost their target innervation, while their cell bodies remain alive but are 
functionally impaired. Removing DJ-1 from these mice might specifically be detrimental for such 
a population of already sensitized neurons, which is why they would be lost in the double 
mutants without causing an additional loss of fibers. Impaired neurons that have lost their target 
innervation may be atrophic and have a reduced cell soma size. If these were to a greater extent 
lost in Ret/DJ-1 double mutants, we would predict that the average cell size of the entire 
population would increase compared to Ret single mutants. To test this hypothesis, I quantified 
cell somas sizes from 24 month old mice in randomly selected SNpc neurons, immunostained for 
the DA marker GIRK2, which selectively labels the neurons that target the dorsal striatum, and 
were more specifically lost than the entire TH+ population (Aron et al. 2010). These results 
showed that the GIRK2+ SNpc neurons in the Ret single mutant mice indeed were smaller than 
in the control mice (figure 2-3a,b). In Ret/DJ-1 double mutant mice, there was a tendency 
towards larger cell size larger compared to Ret single mutants, however due to high variation the 
difference was not significant (figure 2-3b). 
2.1.6. No alterations of DJ-1 or Ret protein levels 
Figure 2-4 No alterations of DJ-1 or Ret protein. Western blots of (a) ventral midbrain lysate from 18 month old 
control, Ret and DJ-1 mutant mice (n=3 mice per group), antibodies: Ret, DJ-1 and Erk1/2 as loading control. (b) 
Striatal lysates from 24 month old control, DJ-1, Dat-Cre, and Ret mutant mice, n=2 mice per group, antibodies: 
Ret, beta-actin, DJ-1. Complete genotypes: mixed controls, DJ-1-/-, DAT-Cre;Retlx/-, DAT-Cre;Retlx/-;DJ-1-/-. 
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Since DJ-1 and Ret interacted genetically, it was possible that DJ-1 protein levels would be 
upregulated in Ret mutant mice, or conversely that Ret protein levels would be upregulated in 
DJ-1 mutant mice. To test this possibility, I collected tissue lysates from the ventral midbrain or 
striatum of 18 or 24 month old mice, respectively, and analyzed by western blot for DJ-1 and 
Ret. (figure 2-4 a,b). The results indicated no major differences in DJ-1 protein levels in Ret 
mutant mice, or in Ret protein levels in DJ-1 mutant mice, but confirmed that Ret protein levels 
were highly decreased by efficient gene recombination in Ret mice and that the DJ-1 protein was 
absent in DJ-1 null mice as expected. 
2.2. Analysis of biochemical pathways that could link DJ-1 with Ret 
signaling in mammalian cell culture 
2.2.1. No evidence of DJ-1 regulating the PTEN-Akt signaling pathway 
The canonical PI3K/Akt pathway is well established to be important for general cell survival 
(Parcellier et al. 2008), and is also thought to be important for survival of dopaminergic neurons 
in particular (Ries et al. 2006). It has been reported that DJ-1 interacts genetically with Akt in 
Drosophila (Y. Yang et al. 2005; R. H. Kim, Peters, et al. 2005), and upregulates Akt 
phosphorylation in mammalian cell culture by negatively regulating PTEN, a PIP3 phosphatase, 
thereby preventing Akt activation (R. H. Kim, Peters, et al. 2005). Since Ret is a known activator 
of PI3K, these reports raised the possibility that combined Ret and DJ-1 activity could lead to 
increased Akt activation. We therefore hypothesized that increased Ret signaling could 
compensate for loss of DJ-1 function by increasing Akt activation. To test this hypothesis, the 
first step was to establish that DJ-1, in agreement with previous studies, indeed regulates Akt 
phosphorylation. To this end, DJ-1 was depleted in HeLa cells using small interfering RNAI 
(siRNA) and subjected to western blot analysis for phospho-Akt. Contrary to our expectations, 
no decrease in phospho-Akt was observed (figure 2-5a). To confirm the results, I performed the 
same experiment in SH-SY5Y (neuroblastoma) and A549 (lung carcinoma) cells, of which the 
latter were used in the Kim et al study, to exclude that a different result was due to the different 
cell type used. However no decrease in phospho-Akt was observed when DJ-1 was knocked down 
(figure 2-5a). Increasing DJ-1 levels using transient overexpression in HeLa cells also did not 
alter the Akt phosphorylation (figure 2-5a). Furthermore, primary MEFs were isolated from 
wildtype and DJ-1 knockout embryos, starved for 6 hours, and stimulated with Insulin-like 
growth factor-1 (IGF-1) for 1, 15 or 120 minutes to test the possibility that DJ-1 regulates 
52  
phospho-Akt in only a particular time-frame. However, no differences between wildtype and DJ-
1 knockout cells were observed (figure 2-5b). In order to exclude that native differences between 
the two cells lines would obscure the results, I overexpressed DJ-1 or GFP in DJ-1 knockout 
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Figure 2-5 No regulation of Erk or Akt activation by DJ-1 in mammalian cell culture. Western blots of lysates from
(a) Ctrl or DJ-1 siRNA transfected HeLa, SH-SY5Y and A549 cells, empty vector or DJ-1-myc plasmid transfected 
HeLa cells, (b) mouse embryonic fibroblasts (MEFs) from wildtype (+/+) or DJ-1 knockout (-/-) mice, treated with
insulin-like growth factor-1 for 1, 15 or 120 minutes, (c) Ctrl siRNA, DJ-1 siRNA, empty vector or DJ-1-myc
plasmid transfected SH-SY5Y cells, (d) DJ-1 knockout MEFs transfected with GFP or DJ-1-myc plasmids, (e) COS7
cells transfected with empty vector or DJ-1 myc plasmids, (f) Two clones (#1,2) of wild type or DJ-1 knockout
MEFs. Antibodies: phospho-Akt, Akt, DJ-1 phospho-Erk1/2, Erk1/2, beta-tubulin, PTEN, as indicated. 
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cells, however no increase in phospho-Akt was observed with DJ-1 overexpression (figure 2-5d). 
If DJ-1 was a negative regulator of PTEN, we would expect PTEN levels to be increased in DJ-1 
knockout MEFs when compared to wildtype MEFs, however I did not observe any differences 
(figure 2-5f). In conclusion, I found no evidence supporting a function of DJ-1 in regulating 
PTEN or Akt activation. 
2.2.2. No evidence of DJ-1 regulating the Ras/Erk signaling pathway 
In Drosophila, our group has previously discovered genetic interactions between components of 
the Ras/Erk pathway and DJ-1 in eye and wing development (Aron et al. 2010). The two 
Drosophila homologs of DJ-1, DJ-1A/B interact genetically with a Drosophila Ras gain-of-
function allele and with a Drosophila Erk (rolled) loss-of-function allele. However, from these 
experiments, it was not possible to deduce at which level of the Ras-Erk pathway, or how, DJ-1 
interacted. To test whether DJ-1 acted upstream of Erk in mammalian cells, DJ-1 was 
overexpressed or depleted from SH-SY5Y cells, but no differences in phospho-Erk were observed 
(figure 2-5c). In addition, western blots using MEFs described above (figure 2-5b,d) were re-
probed for phospho-Erk, but also there no differences were seen (figure 2-5b,d). Later, it was 
reported that DJ-1 overexpression in COS cells increased Erk1/2 phosphorylation (L. Gu et al. 
2009), contrary to my observations in HeLa, SH-SY5Y and MEF cells. To test whether I could 
reproduce these results, I overexpressed DJ-1 in COS7 cells, but did not observe the strong 
increase in phospho-Erk1/2 that was reported (figure 2-5e).  
2.2.3. No evidence of serum or GDNF increasing DJ-1 expression after starvation 
It has previously been reported that DJ-1 expression in cell lines can be strongly induced by 
serum treatment after starvation, and furthermore, that DJ-1 can have a transforming activity, 
which synergizes with Ras overexpression. Nagakubo et al suggest that the induction of DJ-1 is 
mediated by the Ras-pathway (Nagakubo et al. 1997). To test whether DJ-1 expression can be 
induced by Ret, I used SH-SY5Y cells, which express high endogenous levels of Ret. The cells 
were subjected to serum starvation for 48 or 96 hours, after which they were treated with either 
with 10 % serum or GDNF/GFRα1 (50 ng/ml)  for 12 hours. I did not observe any difference 
in DJ-1 protein levels, neither with starvation, nor with GDNF/GFRα1 treatment (figure 2-6a).  
2.2.4. Absence of Ret-mediated regulation of DJ-1 subcellular localization 
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An interesting aspect of the DJ-1 protein is that it can be localized to several different subcellular 
compartments where it can possibly exert different functions. Two groups have previously 
reported that DJ-1 translocates to mitochondria upon treatment with oxidative stress-generating 
agents such as hydrogen peroxide or paraquat (Canet-Avilés et al. 2004; Junn et al. 2009). 
However, the results of these two studies differ in several points: Canet-Avilés et al observed an 
enrichment of mitochondrial DJ-1 after 24 hours of paraquat, while Junn et al found that DJ-1, 
after 3 hours of hydrogen peroxide treatment, translocated to mitochondria, however, after 24 
hours it had moved to the nucleus. Another study also investigated DJ-1 translocation but no 
enrichment in mitochondria after paraquat treatment was seen (L. Zhang et al. 2005). To test 
whether 1) hydrogen peroxide causes DJ-1 translocation to mitochondria and/or nucleus and 2) 
Ret signaling regulates DJ-1 translocation, I serum-starved SH-SY5Y cells for 24 hours after 
which I treated them with hydrogen peroxide, GDNF/GFRα1 or both for 3 or 24 hours. I 
separated crude fractions by centrifugation and analyzed by western blot using CoxIV and Lamin 
Figure 2-6 No regulation of DJ-1 levels or subcellular localization. Western blots of lysates from SH-SY5Y cells, (a)
unstarved or starved for 48 or 96 hours, prior to 12 hours treatment with 10% fetal calf serum or GDNF/GFRα1
(50 ng/ml), (b,c) treated with 50 μm H2O2, GDNF/GFRα1 (50 ng/ml) or a both combined for (b) 3 hours or (c)
24 hours, after which cells were lysed and subjected to a crude subcellular fractionation by centrifugation.
Antibodies: DJ-1, beta-tubulin (cytosolic loading control), Lamin (nuclear loading control), CoxIV (mitochondrial
loading control) as indicated. 
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as 
fractionation controls for the mitochondrial and nuclear fractions, respectively (figure 2-6b,c). I 
could not observe any enrichment of DJ-1 in mitochondria with any of the treatments at either 
time point. The nuclear fraction appeared to be very small and no clear differences were seen 
with the hydrogen peroxide and GDNF treatments. 
2.2.5. DJ-1 depletion causes increased sensitivity to oxidative stress – no evidence of specific rescue 
by Ret signaling 
Cells lacking DJ-1 have been shown to have increased sensitivity to oxidative stress in a number 
of studies (Taira et al. 2004; Martinat et al. 2004; Görner et al. 2007). Since GDNF/Ret 
signaling has reported pro-survival effects in several cell types, it is possible that GDNF could 
rescue the increased cell death caused by DJ-1 depletion. To test this hypothesis, I depleted DJ-1 
using by siRNA in SH-SY5Y cells, and monitored the knockdown efficiency by western blot 
analysis (figure 2-7a). I treated the cells with hydrogen peroxide in a range of concentrations, 
combined with GDNF and GFRα1 (50 ng/ml) or PBS (figure 2-8b). Experiments were 
performed in medium with reduced serum (2 %) since serum contains growth factors that could 
fulfill the same function as GDNF. After 12 hours of treatment, I measured viability using an 
ATP/luminescence-based assay. The results indicated that DJ-1 depleted cells showed increased 
cell death in agreement with previous studies. Samples treated with GDNF showed increased 
Figure 2-7 No rescue of DJ-1 knockdown induced sensitivity to oxidative stress by GDNF treatment. (a) Western
blot of Ctrl or DJ-1 siRNA transfected SH-SY5Y cells, antibodies: DJ-1 and beta-tubulin, (b) cell viability (percent
of Ctrl siRNA at 0 μm H2O2) measured by an ATP-based luminescence assay of Ctrl or DJ-1 siRNA transfected 
cells treated with H2O2 solution at 0-250 μm for 12 hours with or without the presence of GDNF/GFRα1 (50
ng/ml), means from triplicate samples ± SD 
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numbers of cells at most hydrogen peroxide concentrations including the starting point of 0 μM, 
indicating that GDNF either stimulates proliferation, which was previously shown in SH-SY5Y 
cells (Hirata & Kiuchi 2003), or that it prevents the basal level of cell death caused by the serum-
starvation. However, the increased number of cells with GDNF for any given hydrogen peroxide 
concentration was the same for DJ-1 siRNA and control siRNA treated cells, suggesting that 
there was no specific rescue of the additional cell death caused by DJ-1 depletion. 
2.3. Ret signaling regulates mitochondrial dynamics in PINK1 or Parkin 
knockdown cells 
2.3.1. GDNF/Ret reverses mitochondrial fragmentation 
Acute knockdown of Parkin or PINK1 by RNAi in mammalian cell lines causes fragmentation of 
the mitochondrial network (Exner et al. 2007; Dagda et al. 2009; Lutz et al. 2009). It seems that 
the balance between fusion and fission is shifted towards increased fission; however the detailed 
mechanisms remain elusive. To test whether Ret signaling can regulate the mitochondrial 
dynamics balance after Parkin knockdown, I used SH-SY5Y cells, which express high 
endogenous levels of both Parkin and Ret. I depleted Parkin using siRNA, after which I treated 
the cells with GDNF/GFRα1 for three days. Cells were cultured on glass coverslips for imaging, 
and in parallel on culture dishes for western blot analysis, to monitor the efficiency of Parkin 
depletion (figure 2-8a) and the activation of Akt and Erk signaling (figure 2-8b). Mitochondria 
were fluorescently labeled for imaging using the mitochondria-specific dye Mitotracker, and with 
the different treatments blinded, I scored the cells in one of two categories: “tubular” or 
“fragmented” mitochondrial morphology (figure 2-8c, d). Parkin siRNA treated cells were not 
significantly more fragmented than control siRNA cells (figure 2-8d), in contrast to previous 
studies (Lutz et al. 2009). However, this was probably due to the fact that the control siRNA-
treated cells had a high level of baseline fragmentation, and the siRNA transfection was not very 
efficient. In Parkin siRNA cells, treated with GDNF/GFRα1, the population of cells with 
fragmented mitochondria was significantly lower than in Parkin siRNA alone, indicating that 
GDNF/GFRα1 promotes mitochondrial fusion or inhibits fission. To test whether the same was 
true for mitochondrial fragmentation caused by loss of PINK1, I used HeLa cells, which have 
large mitochondrial networks (2-8e). They are also more efficiently transfected than SH-SY5Y 
cells, improving the quality of analysis. I transfected HeLa cells with PINK1 or control siRNA, 
and monitored the RNAi efficiency using RT-PCR, since the PINK1 protein is maintained at 
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low levels under normal conditions, and the commercially available PINK1 antibodies are of low 
quality (figure 2-8f). HeLa cells do not express endogenous Ret, therefore I transiently 
Figure 2-8 GDNF/Ret signaling reverses mitochondrial fragmentation from Parkin or PINK1 knockdown.  (a,b)
Western blots of lysates from SH-SY5Y cells (a) transfected with Ctrl or Parkin siRNA, antibodies: Parkin, 
GAPDH, (b) transfected with parkin siRNA and treated with GDNF/GFRα1 (100 ng/ml), antibodies: phospho-
Akt, Akt, phospho-Erk1/2, Erk1/2, (c) photomicrographs of SH-SY5Y cells labeled with Mitotracker green FM
depicting mitochondria of typical tubular or fragmented morphology, (d) percentage of SH-SY5Y cells with 
fragmented mitochondria, transfected with Ctrl or Parkin siRNA and treated with GDNF/GFRα1 (100 ng/ml) for 
24 hours prior to analysis, (e) 30 cycles RT-PCR of lysate from HeLa cells, transfected with Ctrl or PINK1 siRNA, 
PCR primers for PINK1 or GAPDH, (f) western blot of  lysates from HeLa cells, transfected with Ret9WT and
treated with GDNF/GFRα1 (50 ng/ml) for 18 hours, (g) photomicrographs of HeLa cells labeled with Mitotracker
green FM depicting mitochondria of typical tubular or fragmented morphology, (h) percentage of HeLa cells with
fragmented mitochondria, transfected with Ctrl or PINK1 siRNA, a Ret9WT  plasmid, and treated with 
GDNF/GFRα1 (50 ng/ml) for 18 hours prior to analysis. Averages per (a): 4 (b): 3 independent experiments, means 
± SEM, ** p<0.01, one-way ANOVA, Bonferroni’s post hoc test, n.s.= not significant. 
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transfected a human Ret9 plasmid, and stimulated cells with GDNF/GFRα1. I performed 
western blot analysis to verify Ret overexpression and activity of downstream signaling 
components after stimulation (figure 2-8g). Using the same method as described above, I found 
that after PINK1 siRNA treatment, there was a significantly higher percentage of cells with 
fragmented mitochondria (67%) as compared to control siRNA cells (25 %). The 
GDNF/GFRα1 treated PINK1 siRNA cells showed a strong and significant reduction of 
fragmentation, where only 34 % had fragmented mitochondria, indicating that Ret signaling can 
reverse PINK1 knockdown induced mitochondrial fragmentation. 
2.3.2. Analysis of Ret activated signaling pathways involved in the rescue of PINK1 knockdown 
induced mitochondrial fragmentation 
To investigate which of the signaling pathways mediate this rescue, I used signaling mutant 
versions of Ret9 developed previously (Lundgren et al. 2006; Stenqvist et al. 2008). The RetShc+ 
construct contains two amino acid substitutions, W1056A and E1058D that change the affinity 
of the Shc adaptor protein to Y1062, one of the main signaling tyrosines of Ret. This causes an 
increased activation of the PI3K/Akt pathway compared to RetWT. Conversely, another version, 
RetDok+ (G1063P) has increased affinity to the Dok4/5 adaptors, and interestingly outcompetes 
the binding of Shc and Frs2, causing increased activation of the Ras/Erk pathway with decreased 
activation of PI3K/Akt (Stenqvist et al. 2008). Using these constructs in the same experimental 
setup as described above for PINK1 siRNA, both RetShc+ and RetDok+ were able to reverse the 
mitochondrial fragmentation from PINK1 knockdown (figure 2-9a), suggesting that the effect 
may not require strong Akt activation. The signaling properties of the three different versions of 
Ret9 were examined using western blot analysis for Erk1/2 and Akt phosphorylation. 
Unfortunately, these results showed significant remaining Akt activation with the Ret9Dok+ 
mutant, in contrast to the original publication (figure 2-9b). It still remains possible that the time 
course of or level of activity is shifted in the Ret9Dok+, but the western blot analysis suggests that 
the results of these experiments should be interpreted with caution. 
 
To further study the pathways downstream of Ret, I used kinase inhibitors for the PI3K/Akt and 
Ras/Erk pathways. The compound U0126 selectively blocks Mek1/2 activity, whereas LY294002 
selectively blocks PI3K activity. To find appropriate concentrations of the compounds, I 
incubated HeLa cells for 12 hours with the two compounds in a series of doses (2-9d,e). High 
doses of these compounds caused a high degree of cell death, thus I reduced the incubation time 
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to 3 hours, after which the cells were subjected to western blot analysis (figure 2-9c) for phospho-
Erk1/2 and phospho-Akt. I also tested for nonspecific kinase inhibition of PI3K by U0126 and 
of Mek by LY294002, but no such nonspecificity was seen (2-9f). The kinase inhibitor 
experiment was performed generally as described above using RetWT, with the difference that 
GDNF/GFRα1 and kinase inhibitors were added only three hours prior to analysis, to avoid too 
high levels of toxicity. Using 20 uM of LY294002, a concentration that reduced p-Akt by 
approximately 70%, did not modulate the GDNF rescue. Interestingly, 2 μM of U0126 on the 
other hand, abrogated the rescue effect of GDNF treatment. Increasing the concentration to 10 
Figure 2-9 GDNF/Ret mediated reversal of mitochondrial fragmentation independent of PI3K. (a,c) Percentage
of HeLa cells with fragmented mitochondria, transfected with Ctrl or PINK1 siRNA, and (a) transfected with
Ret9WT, Ret9Shc+ or Ret9DOK+ plasmids, and treated with GDNF/GFRα1 (50 ng/ml) for 18 hours prior to analysis,
(c) treated with U0126 (2 or 10 μm) or LY294002 (20 μm) and GDNF/GFRα1 (50 ng/ml) for 3 hours prior to 
analysis. (b,d,e,f) western blots of lysates from HeLa cells (b) transfected with Ret9WT, Ret9Shc+ or Ret9Dok+, serum
starved and treated with 10% serum or GDNF/GFRα1 (50 ng/ml) for 30 minutes, (d) treated with 0,1,2,5,10 μM
of U0126 for 12 hours, (e) treated with 0,1,2,5,10,20 μM of LY294002 for 12 hours, (f) Ret9WT transfected and
treated with GDNF/GFRα1 (50 ng/ml) in combination with 20 μM LY294002 or 20 μM U0126. Antibodies: Ret,
phospho-Akt, Akt, phospho-Erk1/2, Erk1/2, GAPDH as indicated. Bar graphs depict averages per (a): 4 (b): 3
independent experiments, means ± SEM, ** p<0,01, one-way ANOVA, Bonferroni’s post hoc test, n.s.=not
significant. 
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μM caused mitochondrial fragmentation, also in control siRNA treated cells. These results 
suggest that the rescue by GDNF/Ret signaling may be independent of Akt and that the Ras/Erk 
pathway may be required for rescue, but further studies are required to confirm this conclusion.  
2.4. Genetic analysis of Dret, Parkin and Pink1 functions in Drosophila 
melanogaster 
2.4.1. Genetic epistasis analysis of DretMEN2A and Parkin in the eye system 
The Drosophila compound eye consists of around 800 ommatidia, and each one contains 8 
photoreceptor neurons. The development of the compound eye is a highly regulated process, 
requiring precise cell divisions and programmed cell death. These events are regulated by several 
canonical signaling pathways and receptor tyrosine kinases, for example the Sevenless receptor. 
Alterations in these signaling pathways can cause phenotypes of incorrect number or size of 
photoreceptor neurons, which are seen as a rough eye with altered size, which can be easily 
analyzed. For these reasons, the Drosophila eye system has frequently been used in genetic 
epistasis studies. Overexpression of constitutively active versions of Drosophila Ret, DretMEN2A/B, 
using the eye specific GMR promoter causes a rough eye phenotype, where the photoreceptors 
are enlarged, creating an irregular, rough morphology, while the total size of the compound eye is 
reduced (Read et al. 2005). Our group has previously shown that DretMEN2A/B interacts genetically 
with DJ-1A/B. Expressing DretMEN2A/B in DJ-1A/B null mutant flies rescues the DretMEN2A/B 
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Figure 2-10 No genetic interaction between UAS-parkin and UAS-DretMEN2A in Drosophila eye development. (a-
d) Photomicrographs of compound eyes of flies with indicated genotypes, (e) quantification of eye size, n=10-23 flies 
per genotype, means ± SEM, *** p<0.001, one-way ANOVA, Bonferroni’s post hoc test, n.s.= not significant.
Complete genotypes: (a) Cyo/+;GMR-GAL4/+, (b) UAS-parkin/Cyo;GMR-GAL4/+ (c) UAS-DretMEN2A/+;GMR-
GAL4/+, (d) UAS-DretMEN2A/UAS-parkin;GMR-GAL4/+. 
Results 61 
phenotype, while combined overexpression of DretMEN2A/B and DJ-1A causes an enhanced 
phenotype with an eye even smaller than with DretMEN2A/B alone  (Aron et al. 2010). 
To test whether the Drosophila homolog of Parkin, (park refers to the endogenous Drosophila 
gene and Parkin to the overexpression-construct), interacts genetically with DretMEN2A, analogous 
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Figure 2-11 Minor or no loss of neurons in park or Pink1 mutant flies. (a-c) Photomicrographs whole-mount 
Drosophila brains, immunostained for TH, maximum projections of confocal Z-sections. (a) Maximum projection of 
100 μm thick segment of the posterior brain, with the posterior protocerebral lateral (PPL1) cluster indicated, (b)
high magnification of PPL1 cluster of DA neurons with 90 degree rotation (right) (c) PPL1 DA neurons from 20-25
day old flies of indicated genotypes, (d-g) numbers of TH+ neurons in the PPL1 cluster, n=6-10 flies per genotype, 
means of left and right hemispheres per animal, means per genotype ± SEM, * p<0.05, student’s t-test. Scale bars: (a)
50 μm, (b) 10 μm. Complete genotypes: (d) park2524B-GAL4/TM3, park25::24B-GAL4/park25::24B-GAL4, (e)
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to DJ-1, I used the GMR-GAL4 driver line to overexpress UAS-Parkin and UAS-DretMEN2A/B. I 
acquired photomicrographs of eyes (figure 2-10a) and measured the eye sizes (figure 2-10b). 
GMR-GAL4;UAS-Parkin (GMR > Parkin) showed no alteration in gross morphology compared 
to GMR controls. GMR > DretMEN2A showed a rough gross morphology and reduced eye size as 
previously reported. Flies with combined parkin and DretMEN2A overexpression showed the same 
rough eye as DretMEN2A expressing flies, and also no difference to these in terms of eye size. These 
results indicate that parkin is not a strong modulator of DretMEN2A signaling during eye 
development. 
2.4.2. Small or no loss of dopamine neuron numbers in park and Pink1 mutants. 
The Drosophila brain contains approximately 200 dopaminergic neurons in 15 defined clusters. 
It has been reported by independent groups that park and Pink1 mutant flies lose a small number 
of these neurons during aging. This is most pronounced in the posterior lateral protocerebral 
cluster (PPL1), which in wild type flies contains 12 neurons (figure 2-11a,b). However, reports 
are somewhat disparate regarding the extent of neuronal loss. Some studies have found an average 
loss of four neurons in 30 day old park null mutant flies (Whitworth et al. 2005; Tain, 
Mortiboys, et al. 2009), while other studies did not see any DA neuron loss (J. C. Greene et al. 
2003; Pesah et al. 2004). For Pink1 mutants, the first study reported a loss of two neurons after 
aging (J. Park et al. 2006), but some recent studies found only a loss of one neuron (S. Liu & 
Bingwei Lu 2010; Y. Imai et al. 2010). The discrepancies may be due to different histological 
techniques, or differences in the genetic background of the flies. In mammals it has been shown 
several times that GDNF treatment can protect dopamine neurons from cell death in various 
toxin models of PD. Therefore, we hypothesized that the active Dret (DretMEN2A) can rescue the 
loss of neurons in park and Pink1 mutants. To investigate this, I first assessed whether the 
neuronal loss could be reproduced under our experimental conditions. To this end, I tested two 
different park null mutant lines (park25 and park1) and a Pink1 mutant line (Pink1B9) and aged 
these to 20-25 days. After aging, brains were analyzed using whole-mount immunostaining for 
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tyrosine hydroxylase, after which confocal z-sections were acquired, allowing efficient imaging of 
the complete PPL1 cluster (figure 2-11c). TH+ neurons were counted in a blinded manner. The 
park25 mutant line displayed an average loss of 0.9 neurons compared to controls (figure 2-11d) 
and the other allele, park1, showed an average loss of 1.1 neurons (figure 2-11e). To control for 
modifiers in the genetic background of the alleles, I also crossed the two lines together to analyze 
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Figure 2-12 Enlarged mitochondria in DA neurons of park mutant flies – no rescue by DretMEN2A. (a-d) 
Photomicrographs of whole-mount Drosophila brains from 10-15 day old flies of indicated genotypes, 
immunostained for TH (upper panels) and GFP (middle panels), overlay of the two channels (lower panels), images 
are maximum projections of confocal Z-sections. (e) Photomicrograph of a single TH+ neuron immunostained for 
TH (upper panel) and GFP (middle panel) and an overlay with outlines of the neuron in blue and the mitochondria
in yellow as they were detected by the automated image analysis algorithms (bottom panel), (f) quantification of
mitochondria size, indicating percentage of mitochondria in the size categories <2 μm2, 2-6 μm2 and >6 μm2, (g) 
number of TH+ neurons in the PPL1 cluster, all values are means per animal ± SEM, * p<0.05, **p<0.01,
***p<0.001, student’s t-test. Scale bars (a,e): 10 μm. Complete genotypes: (a) UAS-mitoGFP/+;park25TH-
GAL4/TM6, (b) UAS-mitoGFP/+;park25TH-GAL4/park25, (c) UAS-mitoGFP/UAS-DretMEN2A;park25TH-GAL4/TM6, 
(d) UAS-mitoGFP/UAS-DretMEN2A;park25::TH-GAL4/park25. 
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the transheterozygous condition park25/1. These flies did not display a significant loss of neurons, 
which could indicate that the slightly stronger phenotypes in the park25 and park1 homozygous 
flies may be due to background modifiers (figure 2-11f), but it should be stressed that the 
difference is minuscule. The Pink1 mutant line (Pink1B9) also did not display a significant loss of 
neurons (figure 2-11g). In conclusion, in our experimental conditions, park and Pink1 mutant 
flies lose one or no neurons in the PPL1 cluster after aging to 20-25 days, and therefore we 
decided not investigate the original hypothesis further. 
2.4.3. Enlarged dopamine neuron mitochondria in park mutant flies – no rescue by DretMEN2A 
Park and Pink1 mutant flies show mitochondrial alterations in several tissues, including 
spermatids, flight muscles and also in the dopamine neurons. While the mitochondria have 
highly different morphologies in these three tissues, they are all strikingly enlarged in the 
mutants, and ultrastructural analyses have revealed that they have significantly reduced density of 
cristae, which also appear broken. To test whether Ret signaling can rescue the mitochondrial 
morphological alterations of the PPL1 dopamine neurons, I overexpressed UAS-DretMEN2A in the 
park25 mutant background using the TH-GAL4 driver. I also used an allele for mitochondrial 
targeted GFP, UAS-mitoGFP to genetically label the mitochondria. In control flies (park25/+, TH 
> mitoGFP), the majority of the mitochondria had a tubular morphology (figure 2-12a) and this 
was not altered by DretMEN2A overexpression (figure 2-12b). In park mutant flies, the 
mitochondria showed a strikingly enlarged appearance (figure 2-12c), which was not altered with 
DretMEN2A overexpression (figure 2-12d). The sizes of the mitochondria were quantified using 
automated image analysis algorithms, which identified the TH+ neurons and measured the area 
of the mitochondria within (figure 2-12e). The results showed a significantly decreased number 
of mitochondria smaller than 2 μm2 in park25/25 as well as in park25/25, TH > DretMEN2A, and an 
increased number of mitochondria larger than 6 μm2, however there was no rescue in terms of 
mitochondrial size by DretMEN2A (figure 2-12f). The numbers of TH+ neurons in the PPL1 
cluster was also counted but there were no significant differences between the genotypes (figure 
2-12g). 
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2.4.4. Degeneration of indirect flight muscles in park and Pink1 mutants – a system to study 
genetic epistasis with Dret 
One of the more pronounced phenotypes of park and Pink1 mutant flies is muscle degeneration, 
causing reduced climbing and flying ability; the latter is also manifested by an abnormal wing 
posture. The dorsal longitudinal indirect flight muscles are the largest muscle group in the adult 
fly. Made up of six large muscles on each side along the midline of the thorax, these muscles 
generate the main propellant force required for flying. Park and Pink1 mutant flies have 
previously been shown to have severe alteration in these muscles: they display an irregular 
morphology, muscles may be truncated or absent, and a fraction of the myofibrils often display 
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Figure 2-13 24B-GAL4 > DretMEN2A does not rescue muscle degeneration in park mutant flies. (a-d) 
Photomicrographs of hemi-thoraces stained with phalloidin-alexa568 showing the six dorsal longitudinal indirect
flight muscles (DL-IFM) at low magnification (upper panel) and individual myofibrils at high magnification (lower 
panel) of 2-5 day old flies with indicated genotypes, (e) photomicrographs of typical wild type or short sarcomeres, 
(f) percentage of flies with wild type (blue bars) or short (red bars) sarcomeres. n=5-9 flies per genotype, scale bars: 
(upper panel) 100 μm, (lower panel) 10 μm, complete genotypes: (a) +/+;park25::24B-GAL4/TM3, (b) UAS-
DretMEN2A/+;park25::24B-GAL4/TM6, (c) +/+;park25::24B-GAL4/park25, (d) UAS-DretMEN2A/+;park25::24B-
GAL4/park25. 
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sarcomeres with altered morphology, significantly shorter, with a missing Z-line and an enlarged 
M-line, hereafter referred to as “short”. The different muscle phenotypes are, however, not fully 
penetrant and vary to a high degree in their expressions. In addition to degenerated myofibrils, 
the mitochondria of the muscles are severely distorted as discussed in section 2.4.3. These 
phenotypes appear to become more severe in older flies, which is why it is considered a 
degenerative phenotype, rather than developmental. We decided to use the indirect flight 
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Figure 2-14 24B-GAL4 > DretMEN2A does not rescue mitochondrial morphology in park mutant flies. (a-d)
Photomicrographs of hemi-thoraces stained with phalloidin-alexa568, mitochondria labeled with UAS-mitoGFP, 
DL-IFMs at low magnification (upper panels) and individual myofibrils at high magnification (lower panels) of 2-5 
day old flies with indicated genotypes, n=3-4 flies per genotype, (e-g) Transmission electromicrographs of 
sarcomeres and mitochondria from ultrathin sections of DL-IFMs from 5-7 day old flies at lower magnification 
(upper panel) and higher magnification (lower panel) (h) optical density measurement of mitochondria TEM
captured mitochondria, averages of 46-199 number of mitochondria per fly, n=3-4 flies per genotype, means ± 
SEM, * p<0.01, student’s t-test. Scale bars: (a, upper panel) 100 μm, (a, lower panel) 10 μm, (e, upper and lower 
panels) 1 μm. Complete genotypes: (a) UAS-mitoGFP/+;park25::24B-GAL4/TM3, (b) UAS-DretMEN2A/UAS-
mitoGFP;park25::24B-GAL4/TM6, (c) UAS-mitoGFP/+;park25::24B-GAL4/park25, (d) UAS-DretMEN2A/UAS-
mitoGFP;park25::24B-GAL4/park25, (e) +/+;park25::24B-GAL4/TM3, (f) +/+;park25::24B-GAL4/park25, (g) UAS-
DretMEN2A/+;park25::24B-GAL4/park25. TEM sample preparation and imaging was performed by Marianna Braun, EM-
Histo facility, MPIN. 
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muscles as a system to study genetic epistasis between Dret and park/Pink1 and hypothesized that 
active Dret overexpression can rescue the phenotypes of the park and Pink1 mutants. No rescue 
of muscle or muscle- mitochondrial morphology in park25 mutants by 24B > DretMEN2A 
To test whether DretMEN2A can rescue the muscle degeneration, I used the driver line 24B-GAL4, 
which is expressed in all mesodermal tissue including muscle from the embryonic stage through 
adulthood, to overexpress UAS-DretMEN2A in the park25 mutant line. From this cross, only a small 
fraction of the offspring carried both the UAS-DretMEN2A and the 24B alleles, approximately 
1:1000 flies, suggesting that the DretMEN2A expression in mesoderm may be lethal during 
development. The escapers, together with controls and park25 mutant flies were dissected and 
stained for f-actin using a fluorescent phalloidin conjugate to visualize the myofibrils (figure 13a-
d). Among the different muscle abnormalities, I chose the characteristic sarcomere morphology 
of the park mutant files (‘short’) to score whether this phenotype was rescued (figure 2-13e). 
Approximately 50 % of the park25 mutant flies displayed this morphology (13c,f), and in the 
park25/25, 24B > DretMEN2A flies, this ratio was not significantly different (figure 13d,f). It still 
a b c d
Pink1B9/+, mef2 Pink1B9/Y, mef2mef2 > DretMEN2A Pink1B9/Y, mef2 > , DretMEN2A
e f
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Figure 2-15 mef2-GAL4 > DretMEN2A overexpression causes severe muscle phenotype – no interaction with Pink1 
loss of function. (a-d) Photomicrographs of hemi-thoraces stained with phalloidin-alexa568, with DL-IFMs at low 
magnification (upper panels) and individual myofibrils at high magnification (lower panels) of 1-2 day old flies with
indicated genotypes, n=6-8 flies per genotype, (e,f) photomicrographs of hemi-thoraces under halogen illumination. 
Scale bars: (upper panel) 100 μm, (lower panel) 10 μm. Complete genotypes: (a) Pink1B9::mef2-GAL4/+, (b)
Pink1B9::mef2-GAL4/Y, (c) UAS-DretMEN2A/+;mef2-GAL4/+, (d) Pink1B9::mef2-GAL4/Y;UAS-DretMEN2A/+, FM6/+. 
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remained possible that even though the myofibril morphology was not rescued, the mitochondria 
would be. To investigate this, I again used UAS-mitoGFP to fluorescently label the 
mitochondria. Wild type muscle showed small round mitochondria aligned between the 
myofibrils in a dense row, homogenously spread over the muscle tissue (figure 2-14a). The 
appearance was not changed with DretMEN2A overexpression (figure 2-14b). In the park25 mutant 
flies, the mitochondria were severely enlarged (figure 2-14c), and this was not altered by 24B > 
DretMEN2A overexpression. Transmission electron microscopy (TEM) was also performed to 
examine whether the ultrastructure appearance of the mitochondria was rescued. Wild type 
mitochondria showed densely packed cristae, giving a dark appearance in TEM (figure 2-14e), 
which was quantified by optical density (2-14h). In the park25 mutants, the cristae density was 
significantly decreased and the cristae appear broken (figure 2-14f,h). This morphology was again 
not altered in DretMEN2A expressing mutants (figure 2-14g,h). In conclusion, there was no 
evidence that 24B driven DretMEN2A expression could reduce the phenotypes of the park mutants. 
It should be noted that the flies analyzed were rare escapers from the overall high embryonic 
lethality of the DretMEN2A expression, and it is possible that these flies do not fully represent the 
general population, perhaps due to some genetic compensation.  
2.4.5. Severe muscle degeneration from mef2 > DretMEN2A overexpression 
Since 24B > DretMEN2A expression (1) caused high lethality and (2) did not rescue the park25 
phenotypes, I decided to test another driver line, the myocyte enhancer factor 2 (mef2)-GAL4, in 
which expression is restricted to muscle tissue. Mef2 > DretMEN2A expression in control flies 
caused a severe loss of muscle tissue with remaining myofibrils being abnormally thick, and 
having a completely distorted appearance compared to controls (figures 2-15a,c,e,f). Expressing 
DretMEN2A in the park25 line also caused embryonic lethality. To test if the situation would be 
similar in a Pink1 mutant background, I also examined the Pink1 null mutant line B9. Pink1B9 
flies have highly similar muscle and mitochondrial phenotypes to the park mutant flies, with 
about 60 % of the flies showing the typical “short” myofibril morphology (figure 2-15c). 
Expressing DretMEN2A with mef2-GAL4 in a Pink1 mutant background did not modify the severe 
DretMEN2A phenotype (figure 2-15d).  
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2.4.6. Genetic interaction between mef2 > DretMEN2B and Pink1 in regulating muscle morphology 
The experiment using mef2 > DretMEN2A demonstrated that activated Dret signaling can regulate 
muscle morphology in a powerful manner. The other version of constitutively active Dret, 
MEN2B, previously gave a milder phenotype as compared to MEN2A in eye development (Aron 
et al. 2010). To test the effect of MEN2B in the muscle system, I overexpressed DretMEN2B using 
mef2-GAL4. The flies were viable, but showed muscle morphology with several abnormalities, 
commonly including thicker myofibrils of irregular shape, often with large actin deposits (figure 
2-16a). To investigate whether DretMEN2B interacts genetically with Pink1, I overexpressed it in a 
Pink1B9 mutant background (figure 2-16b-e) and scored the flies for the myofibril appearances 
‘short’, ‘thick/actin blobs’, or ‘wild type’ (figure 2-16f). Of the Pink1B9 mutants, 65% displayed 
Figure 2-16 mef2-GAL4 > DretMEN2B interacts genetically with Pink1 loss of function in regulating myofibril 
morphology. (a-e) Photomicrographs of hemi-thoraces stained with phalloidin-alexa568, with DL-IFMs at low 
magnification (upper panels) and individual myofibrils at high magnification (lower panels) of 2-5 day old flies with
indicated genotypes, photomicrographs of typical wild type, short or thick/frayed myofibrils, in (b) 3 example high 
magnification images illustrate different morphologies, (f) example images of typical wild type, ‘short’, or
‘thick/actin blobs’ myofibril morphologies, (g) percentage of flies with wild type (blue bars), short (red bars) or 
thick/actin blobs (green bars) sarcomeres. n=8-20 flies per genotype, scale bars: (upper panel) 100 μm, (lower panel) 
10 μm. Complete genotypes: (a) Pink1B9::mef2-GAL4/+, (b) Pink1B9::mef2-GAL4/Y, (c) UAS-DretMEN2B/+;mef2-
GAL4/+, (d) Pink1B9::mef2-GAL4/+;UAS-DretMEN2B/+, (e) Pink1B9::mef2-GAL4/Y;UAS-DretMEN2B/+. 
Pink1B9/+, 
mef2 > mitoGFP
Pink1B9/Y, 
mef2 > mitoGFP
Pink1B9/Y, 
mef2 > mitoGFP, DretMEN2B
Pink1B9/+, 
mef2 > mitoGFP, DretMEN2B
a b c d
Figure 2-17 mef2-GAL4 > DretMEN2B overexpression does not rescue mitochondrial morphology phenotype of
Pink1 mutants. (a-d) Photomicrographs of hemi-thoraces stained with phalloidin-alexa568, mitochondria labeled 
with UAS-mitoGFP, DL-IFMs at low magnification (upper panels) and individual myofibrils at high magnification
(lower panels) of 2-5 day old flies with indicated genotypes, n=8-10 flies per genotype, scale bars: (upper panel) 100 
μm, (lower panel) 10 μm Complete genotypes: (a) Pink1B9::mef2-GAL4/+;UAS-mitoGFP/+, (b) Pink1B9::mef2-
GAL4/Y;UAS-mitoGFP/+, (c) Pink1B9::mef2-GAL4/+;UAS-DretMEN2B/UAS-mitoGFP, (d) Pink1B9::mef2-
GAL4/Y;UAS-DretMEN2B/UAS-mitoGFP. 
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the ‘short’ phenotype, the remainder had wild type-like myofibrils (figure 2-16g). Overexpressing 
DretMEN2B in flies heterozygous for Pink1B9 led to 92 % displaying ‘thick/actin blobs’ myofibrils. 
In Pink1B9 mutants overexpressing DretMEN2B, 80 % instead displayed wildtype-like myofibrils, 
with the remaining showing either the “short” phenotype (13 %) or the “thick/actin blob” 
phenotype (7 %). These results indicate that DretMEN2B under control of the mef2-GAL4 driver 
interacts genetically with Pink1 in regulating muscle morphology. 
2.4.7. No rescue of Pink1 mitochondrial phenotype by mef2 > DretMEN2B overexpression 
To test whether DretMEN2B overexpression could rescue mitochondrial abnormalities in the Pink1 
mutants, I used the UAS-mitoGFP allele to genetically label mitochondria in Pink1B9, mef2 > 
DretMEN2B flies. The analysis showed that Pink1 heterozygous controls expressing DretMEN2B had 
normal mitochondrial morphology compared to controls (figure 2-17a,b). Pink1B9 mutants 
showed a mitochondrial phenotype highly similar to the park mutants as reported previously 
(figure 2-17c). In DretMEN2B expressing Pink1B9 mutants, no difference was seen as compared to 
Pink1B9 alone (2-17-d). 
2.5. Function of combined Ret and PINK1/Parkin activity in nigrostriatal 
dopamine neurons of aged mice 
2.5.1. Generation of Ret/PINK1 and Ret/Parkin double mutant mice  
We previously showed that Ret interacted genetically with DJ-1 in the dopamine neurons of the 
SNpc during aging in mice, where 18 month old Ret/DJ-1 double mutant mice had lost a higher 
number of neurons than those of Ret and DJ-1 single mutants combined. Knockout mouse 
models for the two other common genes causing ARPD, Parkin and PINK1, have previously 
been characterized by several different groups, and show no neurodegenerative phenotypes, 
similar to DJ-1 mutants. We now asked whether the genetic interaction between DJ-1 and Ret 
was specific for DJ-1 or also present between Ret and Parkin and/or PINK1. To this end, the 
Dat-Cre;Retlx mice (“Ret”) were crossed to mice with PINK1lx and Parkin- alleles. The use of a 
conditional PINK1 allele would allow us to conclude that a hypothetical genetic interaction 
would be cell autonomous. To be able to directly compare it with results from the Ret/Parkin and 
Ret/DJ-1 situations that are null alleles, we also generated a PINK1- allele by recombining the 
PINK1lx allele in the germ line, mediated by the DAT-Cre recombinase. 
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2.5.2. Normal development of Ret/PINK1 double mutant mice and absence of early 
neurodegeneration 
Ret/PINK1lx, Ret/PINK1- and Ret/Parkin double mutant mice were all viable and did not present 
apparent phenotypes at birth. To assess whether young mice would already show the onset of an 
early neurodegenerative phenotype, a cohort of Ret/PINK1lx and littermate controls were 
sacrificed at 3 months of age. We performed stereological quantifications of TH+ neurons in the 
SNpc and measured the density of TH+ fibers in the striatum but the results showed no signs of 
early neurodegeneration, with equal numbers of TH+ neurons and striatal fibers in controls and 
double mutants (figures 2-18a,b, 2-19a,b).  
2.5.3. No behavioral alterations or neuronal loss in aged Ret single, Ret/PINK1, and Ret/Parkin 
double mutant mice 
At 18 months, we performed a behavioral assessment by measuring activity in an open field arena 
as described previously (see section 2.1.4). The results confirmed that mice carrying the DAT-Cre 
allele are hyperactive compared to controls, but we did not see a difference between PINK1lx and 
Ret or Ret/PINK1lx as in the case of the Ret/DJ-1 analysis (figure 2-18c). Next, we performed 
stereological quantifications of TH+ neurons in the SNpc and unexpectedly, there was no 
reduction in the number of TH+ neurons in Ret single mutant mice compared to controls 
(figure 2-18d). In Ret/PINK1lx double mutants there was a small (21%) but significant reduction 
of TH+ neurons compared to PINK1lx single mutants. Due to delays in the breeding of the 
Ret/Parkin and Ret/PINK1- mice, we did not have more than two mice per group of these double 
mutant lines, however we decided to analyze them to see whether there were any clear 
tendencies.  
2.5.4. Normal density of striatal TH+ fibers in aged Ret and Ret/PINK1 double mutant mice 
Stereological quantifications of Ret, Ret/PINK1- and Ret/Parkin double mutant lines did not 
however indicate any tendencies of loss of DA neurons in these mice (figure 2-18e). To quantify 
the density of striatal TH+ fibers, we developed a new image analysis method based on 
automated recognition of the fibers to measure the image area covered by fibers, divided by the 
total image area, with the striosomal compartment excluded. This method does not require 
manual thresholding of the images, which makes it more unbiased and less time consuming. To 
test the method, 18 month old mice from the previous DJ-1 and DJ-1/Ret colony were analyzed. 
The results were in agreement with the previous data and indicated a 48 % decrease in fiber 
density in DJ-1/Ret compared to DJ-1 alone (figure 2-19c,d). Thus, these results validated that 
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Figure 2-18 No behavioral deficits or loss of TH+ neurons in aged Ret single, Ret/PINK1 or Ret/Parkin double 
mutant mice. (a,d) Photomicrographs of coronal brain sections from 18 months old control, PINK1lx, Ret, and
Ret/PINK1lx mutant mice showing dopamine neurons in the substantia nigra (SNpc) for the DA markers TH. (b,e,f)
Stereological quantifications of DA neurons in SNpc: (b) 3 month old control and Ret/PINK1lx mice, n= 3 mice per 
genotype, (e) 18 month old control, PINK1lx, Ret, Ret/PINK1lx mice, n=4-8 mice per genotype, (f) 18 month old
control, Ret, Ret/ PINK1-, Ret/Parkin mice, n=2-3 mice per genotype, (c) behavioral assessment of control, PINK1lx, 
Ret and Ret/PINK1lx mice in an open-field arena where horizontal movement was automatically tracked during 20 
min, n=4-9 mice per genotype means ± SEM, * p<0.05, one-way ANOVA with Bonferroni’s post hoc test
(stereology), student’s t-test (open-field), n.s. = not significant. Scale bars: (a,d) 250 μm. Complete genotypes: mixed 
controls, DAT-Cre;PINK1lx/-, DAT-Cre;Retlx/-, DAT-Cre;Retlx/-;PINK1lx/-, DAT-Cre;Retlx/-;PINK1-/-, DAT-Cre;Retlx/-
;Parkin-/-. Mice were bred by P. Klein, behavioral testing and perfusion was performed by P. Klein and Daniel Nagel, 
histological preparations, immunostainings and stereological quantifications were performed by D. Nagel. 
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the new method could detect a decrease in fiber density, while at the same time confirming 
previous results of the requirement of Ret for maintaining striatal fibers. Next, we analyzed the 
fiber density of the 18 month old control, Ret, PINK1lx and Ret/PINK1lx double mutants. In 
striking contrast to previous results, we did not observe any decrease of fibers in Ret single or 
Ret/PINK1lx double mutants compared to PINK1lx or heterozygous controls (figure 2-19c,e). 
Finally, we analyzed the TH+ fiber density in 24 month old control, PINK1lx, Ret and 
Ret/PINK1lx mice. As expected, the results showed no reduction of fiber density in the Ret or 
Ret/PINK1lx compared to controls or PINK1 mutants, similar to results at 18 months (figure 2-
19f,g). At this point, we can only conclude that the original Ret and Ret/DJ-1 mouse colonies 
responded highly differently to conditional ablation of Ret in terms of the integrity of the 
nigrostriatal system, than the new Ret, Ret/Pink1, and Ret/Parkin mouse colony. 
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Figure 2-19 No loss of TH+ fibers in aged Ret single or Ret/PINK1lx double mutant mice. (a,c) Photomicrographs
of coronal brain sections from (a) 3 month old control and Ret/Pink1 double mutant mice, (c) 18 month old DJ-1, 
Ret/DJ-1, control, PINK1lx, Ret, and Ret/PINK1lx mice and, (e) 24 months old control, PINK1lx, Ret, and Ret/ 
PINK1lx mice showing axonal fibers of the dorsal striatum stained for the DA marker TH, (b) quantifications of
fiber density using the counting grid method, n=3 mice per genotype, (d,e,f) quantifications of fiber density using
the automated fiber area method, (d) n=2 mice per genotype, (e) n=5-8 mice per genotype, (g) n=3-5 mice per 
genotype means ± SEM, Scale bars: (a,b) 10 μm. Complete genotypes: mixed controls, DAT-Cre;PINK1lx/-, DAT-
Cre;Retlx/-, DAT-Cre;Retlx/-;PINK1lx/-, DJ-1-/-, DAT-Cre;Retlx/-;DJ-1-/-. Mice were bred by P. Klein, perfusions and 
histological preparations were performed by P. Klein and D. Nagel, immunostainings by D. Nagel, microscopy and
image analysis in (e) by D. Nagel and in (d,g) by P. Klein. 
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3. Discussion 
 
The neurotrophic factor GDNF and its receptor Ret have proven to be required for the survival 
of nigrostriatal dopamine neurons during aging in mice, and therefore provide a target for PD 
therapy, currently under clinical development. Although they evidently have a critical function in 
dopamine neurons, the nature of this function remains largely unknown. In this project, we 
investigated whether Ret signaling cooperates with three ARPD-associated genes in maintaining 
critical cellular functions during aging and cellular stress. For this purpose, we have used mouse 
genetics to analyse how double loss-of-function affects dopamine neurons during aging. 
Furthermore, we studied cellular signaling and mitochondrial dynamics in cultured cells, and 
finally, genetic epistatis in Drosophila. We found that combined activity of Ret and DJ-1 is 
required for survival of a population of SNpc dopamine neurons during aging, indicating a 
genetic interaction between the two genes. In biochemical analysis using cultured cells, I found 
no evidence for a function of DJ-1 in regulating either PI3K-Akt, or Ras-Erk signaling pathways, 
in opposition to previously published reports. I also asked whether Ret signaling can compensate 
for loss of Parkin and PINK1, and found a novel function of Ret in reversing mitochondrial 
fragmentation after PINK1 or Parkin knockdown. In Drosophila, I found that constitutively 
active Dret can strongly modify muscle development and can, to some extent compensate, for 
Pink1 loss-of-function in terms of myofibril morphology. However, Dret did not rescue 
mitochondrial impairment of park or Pink1 mutants. Lastly, I investigated how combined loss of 
Ret and PINK1 or Parkin affects the survival of dopamine neurons in aging mice. Unexpectedly, 
I found no signs of neurodegeneration, either in Ret single, or in Ret/PINK1 and Ret/Parkin 
double mutants, suggesting that unknown factors, possibly genetic background, are critical for 
the development of a neurodegenerative phenotype in mice lacking Ret function. 
3.1. DJ-1 is required for survival of a subset of neurons lacking Ret during 
aging 
To test whether Ret and DJ-1 interact genetically, we generated double mutant mice that lack Ret 
in DA neurons, and DJ-1 in all cells, and followed these mice during aging. Intriguingly, these 
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mice showed increased neurodegeneration of nigrostriatal DA neurons compared to Ret single 
mutant mice, which at two years had lost approximately 26 % of their SNpc DA neurons, while 
the double mutant mice had lost 41 %, indicating a strong interaction between the two genes. 
DJ-1 single mutant mice showed no loss of neurons, so it appears that DJ-1 is not critical for 
survival of DA in mice without further insults. However, when the neurons are impaired in 
receiving trophic signaling via the Ret receptor, DJ-1 becomes critical for survival of a subset of 
neurons. When we studied the axonal projections of the nigral neurons in the target area, the 
dorsal striatum, we found that the density of fibers in Ret single mutants was reduced by about 
50 % compared to controls, and interestingly this difference was repeatead in the Ret/DJ-1 
double mutants. The fact that the loss of fibers exceeded the loss of cell bodies in Ret mutants 
was previously known, and indicates that Ret has a critical function in maintaining axons. The 
finding that Ret/DJ-1 double mutants did not lose additional fibers, indicates that DJ-1 does not 
have a function in axon maintenance, but protects against cell death via other mechanisms. 
 
The two datasets of striatal innervation and SNpc cell body numbers create an interesting 
implication: When a neuron dies, its axon usually degenerates with it. Since more cell bodies 
were lost in Ret/DJ-1 double mutants than in Ret single mutants, we would intuitively expect a 
corresponding decrease in fibers. As this was found not to be the case, there are two hypothetical 
models that can explain this data. One possibility is that the remaining neurons in the Ret/DJ-1 
double mutants compensate for the loss of striatal DA fibers by resprouting, thereby increasing 
the number of fibers per neuron (figure 3-1, model A). Alternatively, there could be a population 
of surviving neurons in the Ret mutants that have lost most of their striatal fibers. These neurons 
would be sensitized, and in mice lacking also DJ-1, this population would succumb to a higher 
extent than neurons richer in axonal projections (figure 3-1, model B). We regard the first theory 
of resprouting as more improbable, since it was shown that Ret is required for resprouting after 
MPTP lesions (Kowsky et al. 2007), however, as this is a different genetic model, we cannot 
exclude this theory. We elaborated on the second theory, and further hypothesized that if some 
neurons have lost most of their target innervation, they would be smaller and atrophic, compared 
to the others, as they would have received less trophic support with smaller axonal arbors. If this 
indeed were the case, we would predict a decrease in average cell body size in the Ret mutants 
compared to controls, with an increase in the average size in Ret/DJ-1 double mutants, as the 
atrophic neurons succumb. To test this theory, I measured the cell body size of SNpc DA 
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neurons, and results showed that it was slightly decreased in Ret mutants as compared to 
controls, as predicted. However, in Ret/DJ-1 double mutants, there was no significant decrease 
compared to controls, but also no significant increase compared to Ret mutants, due to variation 
between animals and the small magnitude of difference in the Ret mutants. Because of this, we 
were, unfortunately, not able to conclude from this experiment whether the theory was correct or 
not.  
The behavioral assessment showed that mice carrying the DAT-Cre knock-in allele were 
hyperactive compared to controls, but there was no reduction in Ret single or Ret/DJ-1 double 
mutants as compared to DAT-Cre controls. With only one functional copy of the DAT gene, 
neurons are deficient in dopamine-reuptake at the synapse, which causes increased synaptic 
dopamine levels, similar to the effects of pharmacological DAT inhibitors, such as cocaine. It is 
Figure 3-1 Two models of neurodegeneration of nigrostriatal neurons in Ret single and Ret/DJ-1 double mutant 
mice. 24 month old Ret mutant mice showed a reduction of approximately 25 % of the TH+ SNpc cell bodies and
50 % of the striatal fibers as compared to wild type of DJ-1 mutants (unaffected). Ret/DJ-1 double mutants showed, 
as compared to Ret alone, an increased 41 % reduction of TH+ SNpc neurons, while the density of striatal fibers 
remained unchanged as compared to Ret. Two theoretical models can explain the numbers: In model A, the 
remaining neurons in Ret/DJ-1 double mutants resprout, to compensate for the neuronal loss, (green indicating new
fibers). In model B, a population of neurons has lost most of its fibers and is sensitized (pink), while remaining
neurons have more intact fibers. In Ret/DJ-1 double mutants, the sensitized population is preferentially lost. 
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possible that this effect masks functional impairments that otherwise would be present in the 
double mutants. In fact, the DJ-1 single mutants were hypoactive, while the DAT-Cre carrying 
Ret/DJ-1 double mutants were hyperactive. Measurements of striatal dopamine content showed 
elevated levels in DAT-Cre, Ret single and Ret/DJ-1 double mutants compared to controls, likely 
due to a compensatory upregulation in response to the reuptake deficiency. The fact that 
dopamine content in 18 month old mice was at a similar level in DAT-Cre, Ret single and 
Ret/DJ-1 double mutants, despite approximately 50 % less striatal fibers in the latter two, 
suggests that dopamine synthesis may have been even further upregulated in the mutants. 
Western blot analysis of the rate-limiting dopamine synthesis enzyme TH could not, however, 
confirm this theory, although the analysis, for technical reasons had to be performed in 24 
month-mice, which cannot exclude a down-regulation of TH between 18 and 24 months.  
It remains unclear why combined activity of Ret and DJ-1 is required for maintaining a 
population of dopamine neurons. One possibility is that the Ret and DJ-1 proteins perform 
relatively independent functions in the cell, although the meaning of independence in a cell’s 
physiology is, of course, a matter of definition. Deficiency of one of these functions could 
sensitize the cell, and additional impairment of the second function, could cause cell death. 
Another possibility is that Ret and DJ-1 cooperate in a much more direct way, by regulating the 
same function, for example a particular signal transduction pathway. It is important to note that 
the combined activity of Ret and DJ-1 is not required for cell survival in young mice, as three 
month old double mutants showed normal numbers of neurons – it is only upon aging that their 
functions become critical. Because of this fact, we can narrow down the possible functions of 
both DJ-1 and Ret to aging-dependent processes.  
 
Following this argument, it is of importance to understand what occurs during aging of a DA 
neuron. Aging is a process that involves molecular damage to the cell’s proteome, genome and 
lipids – damage that cannot be fully repaired and therefore, accumulates. DNA damage and 
oxidative stress are two events widely accepted to play a central role in the aging process. 
Superoxide and reactive oxygen species are generated by the electron transport chain of the 
mitochondria, and can cause somatic DNA mutations, modifications of proteins and lipids, 
protein misfolding and aggregation – other processes that are believed to be involved in the aging 
process. Mitochondrial DNA could be particularly vulnerable to oxidative stress due to its close 
physical proximity to the electron transport chain, and indeed mice lacking a mitochondrial 
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DNA transcription factor, have reduced efficiency of mitochondrial biogenesis (Ekstrand et al. 
2007). In addition to producing ATP, mitochondria play a critical role in buffering cellular 
calcium, together with the ER. SNpc DA neurons are unusual in that they rely on the L-type 
voltage gated calcium channel, Ca(v)1.3, for autonomous pacemaking, which causes bigger 
calcium transients than in other cell types. Mitochondria are critical for buffering the calcium 
influx, thus avoiding calcium overload (C. S. Chan et al. 2007). It was recently found that the 
calcium buffering function was impaired in DJ-1 null mice, which was due to decreased 
expression of mitochondrial uncoupling proteins, causing increased oxidative stress and cell death 
(Guzman et al. 2010). It is possible that regulating the expression of mitochondrial proteins, 
required for calcium buffering, is a critical function of DJ-1 during aging. Interestingly, a study 
found that Ret regulates several different types of voltage-gated calcium channels in dorsal root 
ganglionic neurons, specifically via Ras-Erk signaling (Woodall et al. 2008). In addition, GDNF 
was found to regulate A-type potassium channels in midbrain DA neurons, also via Ras-Erk 
signaling (F. Yang et al. 2001). One hypothesis is, therefore, that both Ret and DJ-1 are required 
for controlling calcium homeostasis – Ret controls one or several cation channels via Erk 
signaling, while DJ-1 promotes mitochondrial calcium buffering via upregulation of uncoupling 
proteins. This hypothesis would fit well with the fact that the type of neurons preferentially lost 
in Ret/DJ-1 double mutants have very special calcium/potassium signaling properties as they 
express GIRK2 but not calbindin, and are dependent on Ca(v)1.3 pacemaking. 
3.2. DJ-1 does not regulate Akt or Erk activation in vitro 
Two studies reported that DJ-1 interacts genetically with the PI3K/Akt pathway in Drosophila, 
the second of which, by Mak and colleagues further showed that DJ-1 interacts genetically with 
the phosphatase PTEN. Furthermore, in mammalian cell culture, they found that DJ-1 
dramatically upregulates Akt phosophorylation in COS7, A549, NIH-3T3 and MEF cells. In 
this study, a modest RNAi depletion of DJ-1 caused the normally high levels of Akt 
phosphorylation to decrease to almost undetectable levels (R. H. Kim, Peters, et al. 2005). Such a 
function of DJ-1 creates an interesting direct link to Ret signaling, which is a strong activator of 
PI3K. It would also suggest a mechanism by which DJ-1 and Ret may promote cell survival, as 
Akt is a key regulator of apoptosis and metabolism among other things. Unexpectedly, I found 
no evidence of DJ-1 regulating Akt phosphorylation, although I used similar methods and several 
cell types common to the previous report. The reason the results of our studies differ is unclear. 
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In parallel work from our group in Drosophila, no evidence was found for DJ-1A/B being a strong 
genetic interactor of Akt or PI3K (Aron et al. 2010), again contradicting previous studies. Later, a 
follow up study by Mak and colleagues reported that DJ-1 regulates Akt specifically under 
hypoxic conditions, but in this report the effect under standard oxygen conditions was modest 
(Vasseur et al. 2009).  
 
In work by our group, it was found that DJ-1 interacts genetically with the Ras-Erk pathway in 
Drosophila and later, another group reported that DJ-1 increased Erk1/2 phosphorylation in 
COS7 cells (Aron et al. 2010; L. Gu et al. 2009). In my experiments, I found no evidence for 
DJ-1 as a regulator of Erk1/2 phosphorylation in mammalian cell lines. It remains possible that 
DJ-1 converges with the Ras-Erk pathway downstream of the Erk signaling cascade, but we were 
unable to pinpoint the exact nature of the genetic interaction. Erk1/2 activates major 
transcription factors, such as c-myc and the Cre-binding protein (CREB), and these could be 
possible targets of DJ-1 activity or a DJ-1 regulated pathway. Erk1/2 also regulates translation via 
map-kinase interacting kinase 1/2 (Mnk1/2) and the ribosomal S6-kinases, and DJ-1 has been 
suggested to regulate protein translation in general (van der Brug et al. 2008). 
 
It was previously reported that serum treatment induces DJ-1 expression in HeLa cells, and 
indirect evidence suggested that the effect was mediated via the Ras-Erk pathway (Nagakubo et 
al. 1997). To test whether the same was true for Ret signaling, I used the SH-SY5Y cell line, 
which expresses endogenous Ret, but saw no effect on DJ-1 levels, either after GDNF/GFRα1, 
or serum treatment. I also investigated whether GDNF or oxidative stress could cause DJ-1 to 
translocate between subcellular compartments, as DJ-1 had been reported to localize to the 
cytosol, nucleus, and mitochondria. In my experiments, I conversely found no evidence for a 
significant translocation with 3 or 24 hours of treatment, although the results were somewhat 
difficult to interpret. However, even if such an effect of Ret – regulating either DJ-1 expression, 
or localization – had been present, this type of linear pathway would not fit well with the genetic 
findings from the mouse experiment, where double loss-of-function caused an increased 
phenotype. This type of synergism is rare in genetics and is typically observed by modifying two 
genes that regulate a common target. In such a case, disrupting the function one gene causes 
either a mild, or no phenotype, as the other gene compensates, maintaining the target function. 
However, when disrupting the second gene, the common target is impaired to a greater extent, 
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whereupon a phenotype appears. The recent finding that DJ-1 is required for protecting against 
oxidative stress, by increasing the mitochondrial calcium buffering capacity (Guzman et al. 
2010), would serve as such a candidate target function, and remains to be investigated, 
particularly in the light of our later finding that Ret can control mitochondrial integrity. 
3.3. GDNF/Ret reverses mitochondrial fragmentation after Parkin or Pink1 
depletion – a novel function of neurotrophic factor signaling 
We were interested in studying if Ret signaling converges with the functions of Parkin and 
Pink1, in addition to DJ-1. It had recently been shown that Pink1 and park mutant Drosophila 
have swollen, functionally impaired mitochondria, and that PINK1 or Parkin depleted 
mammalian cells displayed fragmented mitochondrial networks. We decided to test whether 
GDNF stimulation could regulate mitochondrial dynamics in the neuroblastoma cell line SH-
SY5Y after Parkin depletion. Even though the experiments did not fully recapitulate the 
mitochondrial fragmentation after Parkin depletion, it was evident that GDNF/GFRα1 
treatment shifted the balance towards fusion, as both control and Parkin siRNA cells had less 
fragmented mitochondria after the treatment. Using Ret9 transfected HeLa cells, I could further 
show that PINK1 knockdown caused robust mitochondrial fragmentation, which was rescued by 
GDNF/GFRα1 treatment. Since HeLa cells do not express the alternative GDNF receptor 
NCAM, we concluded that the effect is mediated by Ret. To begin dissecting the pathway by 
which Ret reverses mitochondrial fragmentation, the natural starting point was to test which of 
the canonical pathways activated by Ret is required. In order to do this, I first used Ret9 
signaling mutants, Ret9Shc+ and Ret9Dok+, which have altered affinity to the adaptor proteins that 
activated Ret recruits. Ret9Shc+ was reported to increase PI3K activation, while Ret9Dok+ was 
reported to increase Ras activation with significantly decreased PI3K activation (Stenqvist et al. 
2008; Lundgren et al. 2006). The experiment showed that both constructs rescued the 
mitochondrial fragmentation, suggesting that the effect is independent of PI3K/Akt, but western 
blot analysis for phospho-Akt unfortunately showed residual Akt activation by Ret9Dok+. Akt 
phosphorylation was reduced as compared to the Ret9WT, but not fully abolished, and for this 
reason involvement of the Akt pathway cannot be ruled out by this experiment. Another way to 
address the question was to use pharmacological kinase inhibitors. The results indicated that 
when inhibiting PI3K, Ret was still able to rescue mitochondrial fragmentation. On the other 
hand, when inhibiting Mek1/2 in the Ras-Erk pathway, rescue was abrogated. A problem with 
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this approach is that applying pharmacological compounds interfere with the basic physiological 
signaling of the cell, whereas the signaling mutant constructs only modulate the signaling added 
by Ret overexpression. High concentrations of kinase inhibitors are toxic, while low 
concentrations leave residual signaling. In these experiments, even though Akt phosphorylation 
was significantly reduced by the PI3K inhibitor, it cannot be ruled out that a low level of 
activation is sufficient to mediate the rescue. Conversely, it is possible that a high concentration 
of the Mek1/2 inhibitor is toxic, causing fragmentation by a different pathway, and masking the 
rescue. For these reasons, further experiments using independent methods are required to 
characterize the pathway of rescue in detail. 
 
To understand how Ret signaling could reverse mitochondrial fragmentation after PINK1 or 
Parkin depletion, we should first recognize that at least two general scenarios are imaginable: (i) 
Mitochondria could fragment as a secondary consequence of different impairments, such as 
oxidative damage, deficient mitophagy, or other stress factors. It is possible that Ret signaling 
counteracts one of these primary causes, without directly regulating fusion or fission. (ii) On the 
other hand, the opposite scenario is also possible – that Ret signaling targets the physiological 
mechanisms controlling fusion and fission, and by activating Ret, the balance is shifted in the 
direction of fusion irrespective of mitochondrial impairments, or Parkin and PINK1 activity.  
 
If we consider the first scenario, little is known about how Ret signaling may regulate these 
events. It is known that GDNF treatment reduces oxidative stress in rodent models of PD, but 
little is known about the mechanism (M. P. Smith & Cass 2007). It is possible that one of the 
pathways downstream of Ret activates transcription factors, such as Nrf1/2, which are important 
for protection against oxidative stress, and activate mitochondrial biogenesis to replenish the 
mitochondrial pool. Interestingly, Erk1/2 were found to localize to mitochondria in DA neurons 
of Parkinson’s disease brains, and recently, it was shown by the same group that overexpression 
of a constitutively active version of Erk2 was sufficient to induce mitophagy in SH-SY5Y cells (J.-
H. Zhu et al. 2003; Dagda et al. 2008). From these findings we can hypothesize that Ret 
signaling via the Erk pathway may compensate for loss of the PINK1-Parkin pathway by 
promoting clearance of damaged mitochondria by mitophagy.  
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If we instead consider the second scenario, it is known that activities of fission and fusion 
proteins are tightly regulated, and a number of regulatory factors have been identified. The E3 
ubiquitin ligase MARCH5 ubiquitinates all three of the core fusion and fission proteins Drp1, 
Mfn1/2 and Opa1, shifting the balance towards fission. Mitochondrial-anchored protein ligase 
(MAPL) mediated ligation of small ubiquitin-like modifier (SUMO) to Drp1 also promotes 
fission (Westermann 2010). Also the Bcl2-family proteins Bax and Bak were found to regulate 
Drp1 SUMOylation, which is interesting since Bax and several other Bcl2-family proteins are 
regulated by Ret-activated pathways. Bax and Bak associate with Drp1 at fission sites, and this 
was linked to mitochondrial outer membrane permeabilization and apoptosis (Montessuit et al. 
2010; Martinou & Youle 2011). Interestingly however, Bax and Bak were also found to promote 
fusion via Mfn1/2 during physiological conditions (Hoppins et al. 2011; Cleland et al. 2011). 
Furthermore, Drp1 is also regulated by phosphorylation at different positions, which are 
mediated by cAMP dependent kinase (PKA), Ca2+/calmodulin-dependent protein kinase 1 alpha 
(CaMK1alpha) and cyclin-dependent kinase 1 (CDK1). However, Drp1 can also be 
dephosporylated by the protein phosphatase calcineurin, which is activated by Ca2+ (Cribbs & 
Strack 2007; Merrill et al. 2011; Taguchi et al. 2007). One possibility is that Ret signaling 
regulates one of these pathways or, thus far unknown modifiers of the Drp1/Mfn/Opa1 activity. 
3.4. Ret overexpression regulates muscle development in Drosophila but is 
not a strong interactor of Pink1 and park 
Previously, our group has shown that the two Drosophila homologs of DJ-1 interact strongly with 
DretMEN2 and the Ras-Erk pathway during eye development. As an example of this, combined 
overexpression of DJ-1A and DretMEN2A in the compound eye caused a considerably stronger 
phenotype than overexpression of DretMEN2A alone, while DJ-1A alone did not cause any 
phenotype. Here, I asked whether park interacts with DretMEN2A, in a manner analogous to that 
of DJ-1, and to test this, I overexpressed parkin using the same eye-specific driver and the 
DretMEN2A allele. The results revealed no enhanced phenotype with Parkin overexpression, 
indicating that the function of modulating Dret signaling in eye development is specific to DJ-1 
and not present in all ARPD-associated genes. However, in mammalian cell lines, I found a link 
under a different genetic situation - Ret signaling (gain-of-function) modulated phenotypes of 
Parkin and PINK1 loss-of-function. I tested whether this function of Ret is conserved in 
Drosophila, and specifically if DretMEN2A overexpression could rescue some of the phenotypes in 
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park and Pink1 mutants. I first analyzed the dopamine neurons in the PPL1 cluster for their 
relevance in PD, with respect to cell numbers and mitochondrial size. I found the loss of 
dopamine neurons to be smaller than previously reported, as the park mutants showed only loss 
of one out of twelve cells, while Pink1 mutants had a normal number of cells. It is possible that a 
modifier in the genetic background, or increased stress due to particular housing conditions, is 
required to sensitize the flies enough to induce cell death. On the other hand, the reported 
mitochondrial phenotype of the park mutants was well reproduced in my experiment. However, 
overexpressing DretMEN2A using TH-GAL4, did not change mitochondrial size, either in a wild-
type background, or in park mutants.  
 
The indirect flight muscles of park and Pink1 mutants have severely enlarged and dysfunctional 
mitochondria, and in addition, the myofibrils themselves are affected with abnormal sarcomere 
structure. When overexpressing DretMEN2A, driven by the broad mesodermal driver 24B-GAL4, 
the eclosion ratio was very low, indicating that DretMEN2A is likely toxic to one of the targeted 
organs during development. The flies that were analyzed did not show any phenotype as adults, 
but the overexpression also did not modulate the park mutant phenotype. However, being such 
rare escapers, it is likely that these flies do not well represent the true nature of this genotype and 
should perhaps be regarded as abnormal. When instead expressing DretMEN2A using a driver that is 
restricted to somatic muscle cells (mef2-GAL4), the flies displayed highly severe muscle 
degeneration, much stronger than that of park and Pink1 mutants. No genetic interaction 
between DretMEN2A and Pink1 was seen, however with such a strong overexpression phenotype, a 
weak effect of the Pink1 mutant allele may be hard to discern. Overexpression of the other 
constitutively-active allele, DretMEN2B, in the eye causes a milder phenotype than MEN2A, 
suggesting differences between the versions, either in substrate-specificity, or in activity. 
Expressing DretMEN2B alone using the mef2-GAL4 driver caused a weaker phenotype than 
mef2>DretMEN2A, also in the indirect flight muscles, with wider, irregular myofibrils, and frequent 
actin blobs – a phenotype qualitatively different than the park and Pink1 null phenotypes. 
Interestingly, I found that overexpressing DretMEN2B in Pink1B9 mutants largely eradicated both 
phenotypes, producing flies with largely normal myofibril morphology, suggesting partly 
epistatic function. However, there was no rescue of the gross mitochondrial morphology from 
what could be observed by mitoGFP labeling and fluorescence microscopy. It remains possible 
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that DretMEN2B overexpression generates a subtle rescue detectable by ultrastructural analysis, or 
readouts of mitochondrial activity, this possibility remains to be investigated.  
 
It is generally assumed that the myofibril phenotype of Pink1 mutants is caused by events 
downstream of the mitochondrial deficiency, and it is conceivable that it is rescued by DretMEN2B 
without rescuing the mitochondria per se. Another, although unlikely, possibility is that the 
myofibril and mitochondrial phenotypes are due to different functions of Pink1, of which 
DretMEN2B rescues only one. We have not yet found any evidence supporting the hypothesis that 
Dret controls mitochondrial integrity in Drosophila, which is in contrast to the results from 
cultured mammalian cells. However, there are several reasons why this could be the case, as the 
systems are different at several levels. First, the mitochondrial phenotypes of Parkin and Pink1 
loss-of-function are opposite in RNAi treated cultured mammalian cells and in mutant 
Drosophila, in terms of their relation to fusion and fission proteins (see section 1.2.5). If 
mammalian Ret rescues increased fission, but not increased fusion, the results are perhaps 
expected. If, for example, Ret promotes fusion in general, we would actually expect a more severe 
phenotype when overexpressing Dret in the fly. However, I found no notable hyperfusion with 
DretMEN2A/B overexpression in heterozygous control flies, and also no increased mitochondrial size 
in park and Pink1 mutants. Another possible explanation is that Ret protects mitochondrial 
integrity only on a transient timescale after RNAi knockdown followed by GDNF treatment, as I 
did in cell culture, while the genetic modifications in Drosophila may be compensated for on a 
longer timescale. A third possibility is that functional differences between mammalian and 
Drosophila Ret produce the difference. Knowledge of the physiological function of Dret is 
limited and sequence conservation between Dret and mammalian Ret is moderate. Hence, it is 
possible that the function of Dret differs from the mammalian version.  
 
The results from mef2-GAL4 driven overexpression of both DretMEN2 alleles indicate that high 
levels of Dret signaling can strongly regulate muscle development or maintenance. It is unclear 
whether Dret is physiologically expressed in muscle, but in previous expression studies, muscle 
was not mentioned as a tissue with Dret expression, and thus, Dret is likely not a physiological 
regulator of muscle development. However, in overexpression conditions, DretMEN2A/B acts as a 
strong modifier, highlighting the importance of Dret-activated signaling pathways in the muscle 
system.  
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It was recently reported that two translational regulators with opposing functions, Eukaryotic 
translation initiation factor 4E-binding protein (4E-BP) and S6-kinase (S6K), both downstream 
of target of rapamycin (TOR), interact genetically with Pink1 and park. Overexpression of 4E-
BP, or removing its inhibition by TOR by blocking TOR with rapamycin, suppressed Pink1 and 
park phenotypes, by promoting 5’ cap-independent translation (Tain, Mortiboys, et al. 2009). 
Conversely, overexpression of S6K or TOR enhanced Pink1 and park phenotypes, by promoting 
5’ cap-dependent translation (S. Liu & Bingwei Lu 2010). Along the same line, a recently 
published genome-wide screen showed that deficiency of PI3K21B suppressed park and Pink1 
wing posture phenotypes (Fernandes & Rao 2011). PI3K21B is an SH2 adaptor protein of the 
Drosophila PI3K complex, and since TOR is a downstream target of Akt, these three studies 
together suggest that reducing signaling via the PI3K-Akt-TOR pathway suppresses park and 
Pink1 phenotypes by triggering a switch from 5’cap-dependent to 5’cap-independent translation, 
important in stress responses (Holcik & Sonenberg 2005). Since Dret activates PI3K, we could, 
based on these reports, predict that Dret overexpression would enhance the Pink1 and park 
phenotypes. However, this was not the case, since DretMEN2B driven by mef2-GAL4 suppressed 
the myofibril phenotype, and DretMEN2A expressed in DA neurons did not exacerbate the 
phenotype. In a recent genome-wide RNAi screen of regulators of muscle morphogenesis, 
myofibril phenotypes were categorized into a number of classes, and the classes described as 
“Trapezoid” and “Actin blob” had a similar appearance as compared to the DretMEN2B phenotype 
described here. These two classes contain a large number of genes of highly diverse functions, 
including many transcription factors, other DNA binding proteins, and interestingly, regulators 
of metabolism and insulin receptor signaling.  
3.5. Absence of neurodegeneration – importance of genetic background in 
transgenic mouse models 
To determine whether Ret interacts genetically with Parkin and PINK1 in mouse nigrostriatal 
dopamine neurons, we generated compound mice, lacking either Ret and PINK1, or Ret and 
Parkin in dopamine neurons. After the initial study describing mild neurodegeneration after 
conditional ablation of Ret alone, and the finding of increased degeneration in DJ-1/Ret double 
mutants, we were interested to know whether deleting other ARPD genes would also intensify 
the Ret phenotype. We expected one of three outcomes: (i) No enhanced degeneration compared 
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to Ret alone, i.e. loss of approximately 25-30 % of SNpc cell bodies and 50 % striatal fibers at 24 
months. This result would indicate that the interaction with DJ-1 is quite specific. (ii) A similar 
phenotype as compared to Ret/DJ-1, i.e. loss of approximately 40 % neurons and 50 % striatal 
fibers. Such a scenario would suggest that Ret functions synergistically with Pink1 and Parkin 
with the same level of functional significance as with DJ-1, or that any additional stress factor is 
sufficient to cause a mild increased cell death. The last predicted outcome (iii), would be a 
stronger, or qualitatively different phenotype than with DJ-1, e.g. increased loss of cell bodies or 
striatal fibers. This would suggest that Ret interacts genetically with PINK1 and/or Parkin 
through a pathway different to that of Ret/DJ-1. All of these predicted scenarios were of course 
only speculative, as the result of the experiment gave a different conclusion. The outcome was 
instead, that by crossing the Dat-Cre;Retlx mice to Parkin- and PINK1lx lines, it completely 
abrogated the previous neurodegenerative phenotype of the Ret mutants. Importantly, it is not a 
rescue effect of the additional mutations, since Ret single mutants derived from the new 
Ret/PINK1 and Ret/Parkin lines, also did not show neurodegenerative phenotypes.  
 
This leads to the obvious question, why the Ret phenotype is so strikingly different between the 
two experiments? The animals of both colonies were housed in the same animal facility and 
analyzed with genotypes blinded using similar methods, reagents and experimental setups. A 
small group of Ret/DJ-1 mice was reanalyzed together with the Ret/PINK1 mice, and the 
phenotype in the Ret/DJ-1 mice was reproduced as previously described, indicating that technical 
problems of the analysis are unlikely. A possible explanation may instead be found in the genetic 
background. The original DJ-1, Parkin and PINK1 alleles were generated in the Sv129J strain, 
after which they were embryo-rederived into the C57BL/6J strain, crossed to the Dat-Cre and Ret 
alleles, and then intercrossed in a series of breedings. The original Dat-Cre allele was generated 
and kept in the Sv129J background, while the Retlx allele was maintained in a mix of Sv129J and 
C57BL/6J. The complexity of the situation, unfortunately, does not allow a feasible analysis of 
the contribution of each parental strain to the mice that were analyzed. However, it appeared 
from the coat color as if the Ret/DJ-1 line had a higher contribution of Sv129J, as they, in 
general, had brown coats, while the Ret/ PINK1 and Ret/Parkin lines appeared to have 
comparably higher contribution of C57BL/6J, as they typically had black coats.  
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Mouse genetic backgrounds can have profound effects on phenotypic expression of transgenic 
mouse models (Sanford et al. 2001). As an example, EGFR knockout mice in a CF-1 background 
die in the peri-implantation stage due to inner mass degeneration, while in the Sv129 
background, they instead die in the mid-gestation phase due to placental defects. However, in a 
CD-1 background, EGFR knockout mice live up to three weeks after birth, but die due to 
dysfunction in multiple systems (Threadgill et al. 1995). Also, mice mutant for TGF-β, a distant 
homolog to Ret, were demonstrated to display different phenotypes depending on the genetic 
background (Bonyadi et al. 1997). A recent genomic study compared whole genome sequences of 
seventeen common laboratory mouse strains, and found 56 million unique sites of differences 
between all the strains (Keane et al. 2011). Furthermore, by performing a single cross between 
two of the strains, they could show how the two allelic variants were expressed in highly different 
ratios between different tissues, which suggests that gene expression may be one mechanism, by 
which allelic variants can give rise to different phenotypes 
 
Expression of traits is not only determined by genetic variants - also epigenetic variation can be 
inherited, and modify the expression of traits. The suggested implication from this study, that 
genetic or epigenetic background modifiers can cause such a dramatic difference in the 
neurodegenerative phenotype of Ret mutant mice, is interesting. As of today, this is of course 
highly speculative, as direct evidence is missing. However, it is possible that these types of 
differences may play an important role for the risk of humans developing PD. Dissecting the 
background variations between the strains analyzed here, with the goal of identifying critical 
modifiers, is theoretically interesting, but unfortunately a highly extensive experiment and 
beyond the scope of this project. 
3.6. Concluding remarks and future perspectives 
In this thesis, I present evidence that the neurotrophic factor receptor Ret may converge with the 
functions of ARPD-associated proteins. Conditional ablation of Ret in dopamine neurons of 
mice sensitizes a population of neurons, making DJ-1 critical for survival. When also the DJ-1 
gene is deleted, this population of sensitized neurons succumbs during aging. To understand 
which critical cellular functions Ret and DJ-1 maintain, understanding of the aging process is of 
central importance, since aging is an absolute requirement for DA neuron cell death in Ret and 
Ret/DJ-1 double mutant mice. Aging is also the number one risk factor for developing PD, but 
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our knowledge of the underlying mechanisms, is limited. Connecting the aging process with the 
functions of PD-associated genes and neurotrophic factor receptors may identify novel targets for 
therapeutic development.  
 
In the second part of my project, I found that Ret signaling can regulate mitochondrial dynamics 
in cultured cells. Mitochondria play an important role in normal cellular aging. They have 
physiological functions in ATP production, calcium-buffering capacity, and in the initiation of 
programmed cell death. When impaired, they generate undesirable reactive oxygen species, which 
damage the cell. The PD-associated proteins Parkin and PINK1 have been shown to help the cell 
maintain a healthy pool of mitochondria, by clearing damaged ones through mitophagy, and 
promoting the generation of new ones by increasing transcription of mitochondrial proteins. If 
Ret signaling, also under physiological conditions in DA neurons, helps in maintaining a healthy 
pool of mitochondria, it would explain why DA neurons in Ret mutant mice slowly degenerate. 
It would also explain why Ret stimulation by GDNF protects DA neurons in PD models, 
although the effect of reversing mitochondrial fragmentation in cultured cells may be something 
that is only seen in this rather artificial system. It would be highly interesting to learn whether 
GDNF treatment in mouse models of PD, with mitochondrial defects, also protects against 
mitochondrial pathology. Moreover, our knowledge of the pathway by which Ret targets 
mitochondria is at this point very limited. Studying changes in the mitochondrial proteome and 
phosphoproteome after GDNF treatment may give interesting leads into the mechanism. 
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4. Materials and Methods 
4.1. Buffers, media and reagents  
Table 4-1 General purpose buffers 
PBS 10 mM Na2HPO4 pH 7.4 
2 mM KH2PO4 
0,137 M NaCl 
2,7 mM KCl 
TBS 50 mM Tris pH 7.4 
150 mM NaCl 
TBST (biochemistry) 1X TBS 
0,1% TritonX-100 
TBST (histology) 1X TBS 
0,1% Tween 
PFA 4% 1L: 40 g paraformaldehyde in 900 ml H2O, heat to 65°C. Add 400 μL 
NaOH 5M, then neutralize with 150 μL HCl 37 %. Add 100 ml 10X PBS. 
 
Table 4-2 Solutions for mouse histology and genotyping 
Chloral hydrate 8 % chloral hydrate (Roth, Germany) in PBS 
Sucrose solutions 15 % and 30 % sucrose in PBS 
used for brain immersion 
Cryoprotection solution (1L) 300 mL distilled water 
300 mL glycerol 
300 mL Ethyleneglycol 
100 mL PBS 
used to store mouse brain sections at -20 C 
Egg embedding mix egg yelow and sucrose 10 : 1 (g/g) 
use cold mix for embedding (4 C) 
to polymeraze, add 1 mL glyceraldehyde 25 % to 
20 mL egg mix; mix well and allow 45 min for 
after polymerization at r.t., store at -80C 
Tail lysis 25 mM NaOH, 0.2 mM EDTA 
Neutralization: Tris HCl 1,5M pH 8.8 
Blocking buffer 1X PBS 
5% bovine serum albumin (BSA) 
Antibody incubation buffer 1X PBS 
2% BSA 
0,1% Triton-X100 
Mounting medium (1L) Add Celvol205 (Calvanese Chemicals) to 800 ml 1XPBS, adjust to pH 7.2. 
Stir for 24 hours at RT, add 400ml glycerol and stir another 24 hours at RT. 
Remove undissolved Celvol by centrifugation at 12000rpm for 30 min. Add 
H20 to adjust to preferred viscosity. Keep aliquots at -20°C for long-term 
storage. 
  
 
Table 4-3 Solutions for SDS-PAGE/Western blot analysis 
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Cell lysis buffer 1% Triton X-100 
150 mM NaCl  
1mM EDTA 
10 mM Tris-HCl (pH 7.5) 
100 mM NaF 
1 mM NaVO3 
10 mM Na4P2O7 
Brain lysis buffer 150 mM NaCl 
50 mM Tris_HCl, pH 7.4 
2 mM EDTA 
1% Nonidet P-40 
1% SDS 
Reducing sample buffer for SDS 
PAGE 
300mM Tris·HCl pH 6.8 
12% SDS 
600mM DTT 
0.6% (w/v) Bromophenol-blue 
60% glycerol 
Blocking solution 5% non-fat dry milk in TBST 
Stripping solution 1x PBS 
2% SDS 
0,14% β-Mercaptoethanol 
 
Table 4-4 Solutions for fly histology and genetics 
Standard fly food (1L) 15 g yeast 
11.7 g agar 
80 g molasses 
60 g corn flower 
6.3 ml propionic acid 
2.4 g methylparaben 
yeast paste (yeast granules 
Longevity assay fly food (1L) 70 g sucrose 
35 g cornmeal 
5 g agar 
50 g yeast 
4,5 ml propprionic acid 
Squishing buffer 10 mM Tris-HCl pH8  
1 mM EDTA  
25 mM NaCl  
200 g/ml Proteinase K 
Blocking buffer 1X PBS 
5% fetal calf serum 
0,1% Triton-X100 
PFA fixative solution 1X PBS 
4 % PFA 
0,1% Triton-X100 
Phalloidin staining 1X PBS 
0,1% Triton-X100 
Phalloidin-Alexa568, 1:1000 (Invitrogen) 
Mounting medium Vectashield mounting medium H-1000 (Vector Laboratories) 
 
Table 4-5 Buffers for molecular biology 
Tris/EDTA (TE) buffer 10 mM Tris·Cl, pH 8.0  
1mM EDTA, pH 8.0 
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Tric/acetate/EDTA (TAE) buffer 50× stock solution (1L):  
242 g Tris base 40 mM Tris·acetate  
57.1 ml glacial acetic acid 2 mM Na2EDTA·2H2O  
H2O up to 1 liter 
Gel loading buffer 25 ml Glycerol  
1 ml 50X TAE  
0.1 g Orange G  
24 ml H2O  
 
Table 4-6 Cell culture media a reagents 
Cell culture media  
Embryo suspension medium (1L) Dulbecco's modiﬁed Eagle's medium (DMEM) high glucose, Hepes+ 
(Invitrogen) 
1ml Penicillin/Streptamycin 10,000 units (Penstrep) 
MEF-P0 medium (1L) DMEM  
15% fetal calf serum 
1% 1x non-essential amino acids 
1 ml 1x penstrep 
MEF culture medium (1L) DMEM  
9% fetal calf serum 
1% 1x non-essential amino acids 
1% 1x penstrep 
DMEM culture medium DMEM  
10% fetal calf serum 
1% L-Glutamine 
1% pen/strep 
SH-SY5Y medium DMEM/F12 (1:1) with GlutaMAX (Invitrogen) 
10% fetal calf serum 
1% pen/strep 
  
Transfection reagents  
Calcium Phosphate Transfection Kit   K2780-01, Invitrogen 
Lipofectamine 2000 11668-019, Invitrogen 
Lipofectamine RNAiMAX 13778-150, Invitrogen 
  
Cell viability assay  
CellTiter-Glo Luminescent Cell 
Viability Assay 
G7571, Promega 
 
 
Table 4-7 PCR primers 
Primer name Sequence (5’ to 3’) 
DJ-1 Forward AGG CAG TGG AGA AGT CCA TC 
DJ-1 Reverse WT AAC ATA CAG ACC CGG GAT GA 
DJ-1 Reverse mutant CGG TAC CAG ACT CTC CCA TC  
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Pink1 wt forward ACC CCA GAA ACC AAC AAG TG 
Pink1 lx  reverse TGG CCT GAG ACC TTG TCT TT 
Pink1 reverse AAG GAG CAG AGT CCG AGG TT 
NeoR forward TGA ATG AAC TGC AGG ACG AG 
NeoR reverse AAT ATC ACG GGT AGC CAA CG 
Parkin wt forward TGC TCT GGG GTT CGT C 
Parkin ko forward TTG TTT TGC CAA GTT CTA AT 
Parkin ko reverse TCC ACT GGC AGA GTA AAT GT 
Retlx Forward CCA ACA GTA GCC TCT GTG TAA CCC C 
Retlx Reverse GCA GTC TCT CCA TGG ACA TGG TAG 
Retrec Forward CGA GTA GAG AAT GGA CTG CCA TCT CCC 
Retrec Reverse ATG AGC CTA TGG GGG GGT GGG CAC 
Cre Forward GCC TGC ATT ACC GGT CGA TGC AAC GA 
Cre Reverse GTG GCA GAT GGC GCG GCA ACA CCA TT 
h PINK1 RT forward TGG CCC CAG AGG TGT CCA CG 
h PINK1 RT reverse CGC TGG AGC AGT GCC CTC AC 
hGAPDH RT forward GTC GCC AGC CGA GCC ACA TC 
hGAPDH RT reverse TGA CCT TGG CCA GGG GTG CT 
 
Table 4-8 Plasmids 
DJ-1 (pCMV-myc) Phillip Kahle, Hertie Institute, Tübingen 
pCMV Myc empty vector Phillip Kahle, Hertie Institute, Tübingen 
hrGFP (pCDNA3) Edgar Kramer, Universität Hamburg, Hamburg 
Ret9 (pJ7omgea) Patrik Ernfors, Karolinska Institutet, Stockoholm 
Ret9-Shc+ (pJ7omgea) Patrik Ernfors, Karolinska Institutet, Stockoholm 
Ret9-Dok+ (pJ7omgea) Patrik Ernfors, Karolinska Institutet, Stockoholm 
 
Table 4-8 siRNA oligos   
DJ-1 AGGAAAUGGAGACGGUCAUCCCUGU Stealth RNAi, Invitrogen 
DJ-1 CTRL ACAGGGAUGACCGUCUCCAUUUCCU Stealth RNAi, Invitrogen 
Parkin GGAGAGAACCUCAACCGCUAGGAUA Stealth RNAi, Invitrogen 
Parkin scrambled UAUCCUAGCGGUUGAGGUUCUCUCC Stealth RNAi, Invitrogen 
PINK1 #VHS50790 Validated Stealth RNAi, 
Invitrogen (set of 3) 
Medium GC negative control #12935-300 Stealth RNAi, Invitrogen 
 
Table 4-9 Recombinant proteins 
Mouse Insulin-like growth factor 1 (IGF-1) Shenandoah Biotechnology 
Human Glia cell line-derived neurotrophic factor (GDNF) Shenandoah Biotechnology 
Human GDNF family receptor 1 (GFRα1) R&D Systems 
 
Table 4-10 Antibodies  
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4.2. Molecular biology 
4.2.1. Tail DNA preparation and genotyping  
Tail biopsies (1-3 mm) were taken from mice and incubated at 95 °C three times for 15 min in 
100 μl of 50 mM NaOH and vortexed thoroughly between heating steps. Samples were then 
centrifuged to precipitate the remaining debris and the mix was neutralized with the addition of 
10 μl 1.5 M Tris-HCl, pH 8.8 and stored at 4 °C. PCR was carried out in a total volume of 25 
μl and contained 2.5 mM dNTPs, 200 nM specific primers, 1X PCR buffer (NEB), 0.1 μl of 
Taq polymerase (NEB) and 2 μl of tail DNA lysates. PCR samples were analyzed by agarose gel 
electrophoresis in gels of 2% agarose in TAE buffer with 30 μl ethidium bromide per liter gel 
solution. 
Antibody Species Source Dilution Application 
Primary antibodies     
AKT rabbit #9272, Cell Signaling Technology 1:1 000 WB 
phospho-AKT S473 rabbit #9271, Cell Signaling Technology 1:1 000 WB 
phospho-AKT S473 rabbit #4060, Cell Signaling Technology 1:5 000 WB 
 p42/p44 MAPK rabbit #9102, Cell Signaling Technology 1:1 000 WB 
 phospho-p42/p44 MAPK rabbit #4376, Cell Signaling Technology 1:1 000 WB 
 phospho-p42/p44 MAPK rabbit #4370, Cell Signaling Technology 1:3 000 WB 
Ret goat #70R-RG002, Fitzgerald 1:1 000 WB 
DJ-1 goat # ab4150, Abcam 1:1 000 WB 
PTEN rabbit #9559, Cell Signaling Technology 1:1 000 WB 
Tyrosine hydroxylase mouse # 22941, Immunostar 1:2 000 IHC 
Tyrosine hydroxylase rabbit # ab152, Millipore 1:1 000 IHC 
GIRK2 rabbit #APC-006, Alamone Labs 1:80 IHC 
COX IV rabbit #4850, Cell Signaling Technology 1:5 000 WB 
Lamin rabbit #ab2559, Abcam 1:1 000 WB 
Parkin mouse #4211, Cell Signaling Technology 1:1 000 WB 
β-actin mouse #A5316, Sigma 1:20 000 WB 
β-tubulin (T-8660, Sigma). mouse #T-8660, Sigma 1:20 000 WB 
GFP rabbit #A11122, Invitrogen 1:2 000 IHC 
     
Secondary antibodies     
anti-mouse HRP sheep GE Life Sciences 1:5 000 WB 
anti-rabbit HRP goat GE Life Sciences 1:5 000 WB 
anti-goat HRP rabbit DAKO 1:5 000 WB 
anti-rabbit-alexa488 goat Molecular probes 1:1 000 IHC 
anti-mouse-Cy3 donkey Jackson Immunoresearch 1:1 000 IHC 
anti-rabbit-biotin donkey Vectorlabs 1:500 IHC 
Streptavidin-Cy3  Sigma-Aldrich 1:1 000 IHC 
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4.2.2. Preparation of plasmid DNA  
Plasmid DNA was purified from 500 ml bacterial cultures. Single colonies of transformed 
bacteria were picked from LB plates containing ampicillin and inoculated into flasks containing 
LB medium with 100 μg/ml ampicillin and grown overnight shacking at 37 °C. Harvesting and 
purification of maxipreparation was carried out according to Qiagen protocol using Qiagen 
buffers. The DNA concentration was measured in a UV spectrometer at 260 nm. 
4.2.3. Preparation of RNA and quantification by RT-PCR 
RNA from HeLa cells was prepared using RNeasy Mini Kit (Qiagen). Briefly, cells were scraped 
on ice in lysis buffer RLT, passaged through a Qiashredder column for homogenization. One 
volume of 70 % ethanol was added to the lysates and the solution was transferred to an RNeasy 
spin column, which binds the RNA on centrifugation. The column was washed with RPE buffer, 
after which the RNA was eluted in H2O and the RNA concentration was measured with a UV 
spectrophotometer at 260 nm. For the reverse-transcriptase PCR (RT-PCR) analysis, the 
OneStep RT-PCR kit (Qiagen) was used according to the manufacturer’s instruction. For each 
reaction, 100 ng of RNA, 6 μM specific primers and 1 μl enzyme mix was used in a 25 μl 
reaction volume. After reverse transcription, cDNA was amplified by 30 PCR cycles. 
4.3. Cell culture, in vitro assays and biochemistry  
4.3.1. Preparation of mouse embryonic fibroblasts and transfection 
14,5 days pregnant C57BL/6 mice were sacrificed, and the uterus extracted was placed in cold 
PBS. The embryos were extracted and placed in cold embryo suspension medium. The head and 
abdominal/thoracic organs were removed; the remaining tissue was minced using a scalpel and 
further homogenated by passing through hypodermic needles of decreasing diameters. The tissue 
homogenate was digested by incubating with trypsin for 10 minutes in a 1:1 ratio of cell 
suspension to trypsin. Trypsin digestion was repeated with a second volume, the mixture was left 
to settle for 2 min, after which the cell fraction was recovered by decanting. Cell suspension was 
plated at a density of 5 x 106 cells in one 15 cm tissue culture dish in MEF-P0 medium. After 4 
days in culture, cell were passaged and cultured up to 6 passages in MEF culture medium. Cells 
were transfected using the standard Calcium phosphate-precipitate method. 
4.3.2. Transfection of cell lines 
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HeLa cells were transfected using Lipofectamine 2000 for plasmids and Lipofectamine 
RNAiMAX for siRNA by the forward transfection method, according to manufacturer's 
instructions. SH-SY5Y and A549 cells were transfected using Lipofectamine 2000 for plasmids 
or Lipofectamine RNAiMAX by the reverse transfection method, according to the 
manufacturer's instructions. Plasmid overexpression experiments were incubated for 24 h after 
transfections before analysis for all cell types. For DJ-1 western blot experiments, siRNA 
knockdowns were incubated for 48 h after transfection for HeLa and A549 cells, while SH-SY5Y 
cells were incubated for 96 h after transfection before lysis.  
4.3.3. Western blotting 
Cultured cell lines were harvested in lysis buffer with complete protease inhibitor mixture (Roche 
Diagnostics). Mouse brains were snap frozen, ventral midbrains and striata were dissected on ice, 
and homogenized in homogenizing buffer with complete protease inhibitor mixture (Roche 
Diagnostics) by 10 strokes using a dounce homogenizer. Cell lysates and brain homogenates were 
centrifuged at 1,000 g for 10 min, supernatants were saved, and the protein concentration was 
determined using the DC protein assay (BioRad). Samples were denatured by boiling in SDS-
sample buffer; proteins were separated by SDS-PAGE according to standard procedures. Gels 
were transferred to nitrocellulose membranes (Protran, Schleicher&Schuell) by semi-dry blotting. 
Membranes were blocked for 45 minutes in non-fat dry milk solution, incubated with primary 
antibodies in blocking solution over night at 4ºC or for 1 hour at RT, washed 3 x 5 min in 
PBST, incubated with secondary antibodies in blocking solution for 1 hour at RT and again 
washed 3 x 5 min in PBST before incubation with ECL solution (GE Life Sciences) for 1min. 
To visualize signals, membranes were either exposed on X-ray films (GE Life Sciences), or 
imaged with a Fusion FX7 digital camera system (PeqLab). Membranes were stripped in 
stripping solution for 30min at 65ºC and washed 3 x for 10min each in PBST at RT, if 
subsequent detection of another protein was necessary. After stripping, membranes were again 
blocked and treated as described above. 
4.3.4. Cytotoxicity assay 
SH-SY5Y cells were transfected with DJ-1 or CTRL siRNA, and cultured for 4 days for protein 
depletion. Next, cell were plated in 96 well plates at a density of 10 000 cells/well and cultured 
for another 8 hours. The medium was then exchanged to DMEM with 2% FCS, after which 
hydrogen peroxide in a series of concentration together with GDNF (50 ng/ml) and GFRα1 (50 
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ng/ml) or PBS was added. After 12 hours, viability was determined using the ATP/luminescence-
based Celltiter Glo assay (Promega) according to the manufacturer’s instructions. 
4.3.5. Analysis of mitochondrial fragmentation 
SH-SY5Y cells were transfected with Lipofectamine RNAiMAX with Parkin or a scrambled Ctrl 
siRNA over night by the reverse transfection method onto 13 mm glass coverslips. After 
transfection, the medium was changed to standard culture medium and incubated for 48 hours. 
GDNF (100 ng/ml) and GFRα1 (100 ng/ml) was added to the cell and incubated for another 24 
hours. After this, Mitotracker Green FM  (200 nm) (Invitrogen) was added to the cells and 
incubated for 15 minutes to label the mitochondria, and washed 3 x 10 minutes with culture 
medium. The coverslips were placed in metal holders with the cells covered in PBS with calcium 
and magnesium. The samples were blinded to the experimenter, and after this, the living cells 
could be image from underneath in a Zeiss Axioplan fluorescence microscope. Random fields 
were selected and within each field all cells were classified and counted by the morphology of the 
mitochondria as “tubular” or fragmented”.  HeLa cells were transfected with Pink1 or scrambled 
Ctrl siRNA in 6 cm plates. After 48 hours, the cells were resuspended and reverse-transfected 
with a Ret9-wt, Ret9-Shc+ or Ret9 Dok+ in a pJ7omega expression vector (Stenqvist et al. 2008; 
Lundgren et al. 2006). After 8 hours, the medium was changed to standard culture medium, 
GDNF (50 ng/ml) and GFRα1 (50 ng/ml) was added and incubated for another 18-22 hours. 
For kinase inhibitor experiments, GDNF/GFRα1 (50 ng/ml) together with the kinase inhibitors 
LY-294002 (PI3K), U0126 (Mek1) or DMSO was added 16 hours after Ret transfection and 
incubated for 3 hours. After GDNF/GFRα1 and/or inhibitors, cells were stained with 
Mitotracker Green FM and analyzed as described above. 
4.4. Mouse genetics, histology and behavior 
Table 4-11 Transgenic mouse lines 
Allele Description and reference 
Retlx The Ret allele was targeted with a construct with loxP sites flanking exon12 The FRT flanked 
neomycin selection cassette was excised with Flp recombinase (Kramer et al. 2006).  
DJ-1- Gene trap targeting construct containing a splice acceptor, LacZ and neomycin recistance inserted 
between exons 6 and 7, creates a null allele (T.-T. Pham et al. 2010). 
DAT-Cre Knock-in of Cre recombinase into the 5’ UTR of the DAT locus, expressing Cre specifically in 
dopaminergic neurons. Causes loss of function of the dopamine transporter gene. 
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PINK1lx Exon 2-3 flanked by loxP sites and a neomycin resistance cassette within, before exon 2, flanked by 
FRT sites (Wolfgang Wurst, unpublished). 
PINK1- Cre mediated germ-line recombination of the Pink1lx alleles deletes exon 2-3 and creates a null 
allele. 
Parkin- Gene targeting replaced exon 3 and parts of intron 3 with a neomycin resistance cassette, creating a 
null allele (Itier et al. 2003).  
All lines were maintained in a mix of Sv129 x C57BL/6 background. 
4.4.1. Cardiac perfusion, preparation of mouse brains and cryosectioning 
Mice were anaesthetised with an intraperitoneal injection of 8% chloralhydrate. Skin and ribcage 
were cut open and the diaphragm was removed. A small incision was made into the right atrium 
and a needle connected to a peristaltic pump was inserted into the left ventricle and 25 ml of 
cold PBS was run through the animal’s vascular system. This was followed by 25 ml of cold 4% 
PFA solution for fixation. Brains were removed from the scull and transferred to 4% PFA 
solution for post-fixation over night. Next, brains were treated for cyroprotection by incubation 
in 15 % and 30 % sucrose solutions. Left and right brain hemispheres were embedded separately 
in egg yolk with 10 % sucrose and 5 % glutaraldehyde, and kept frozen at −80°C until analyzed. 
30 μm–thick coronal sections were cut on a cryostat, collected free floating, and used for 
immunohistological staining. 
4.4.2. Immunostaining 
Free floating sections were first incubated 1 hour in blocking buffer at RT. The primary antibody 
in antibody incubation buffer was added, and sections were incubated over-night at 4°C. After 
three washes in PBS (5 minutes each), the sections were incubated 1 hour at RT with biotin-
coupled secondary antibodies (dilution 1:200 in antibody incubation buffer) from Vectastain 
ABC kits (Vector Laboratories). After another three washes in PBS, sections were incubated with 
a complex of avidin-biotin coupled to horseradish peroxisade (HRP; dilution 1:200 in PBS 
buffer; incubation 1 hour at RT). After three washes in PBS, the HRP substrate 
diaminobenzidine (DAB; Sigma-Aldrich, Germany) - diluted in tap water was added. Sections 
were incubated until a brown precipitate was formed.  
4.4.3. Stereological quantification of neuron numbers 
Stereological counts were performed with the StereoInvestigator software (MicroBrightField, 
Williston, Vermont, United States) on every sixth section of the SN or VTA. After 
immunolabeling of SN neurons, the exact order of sections spanning the midbrain area was 
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established. On each individual section, the area of the SN or VTA was delineated and an 
automated method allowed selection of smaller a 50 x 50 μm square, distributed on a grid with 
the dimension 125 x 125 μm. Within each automatically selected square, neurons were counted 
when there somas were in focus within a 10 μm segment on the Z-axis in the center of each 
section. By this method, a minimum of 200 cells per animal were counted. After all sections were 
processed, the program used the determined neuronal densities to extrapolate the total number of 
neurons found within the selected volume.  
4.4.4. Quantification of striatal fiber density by counting grid  
For every sixth 30 μm thick section, 4 images in dorsal striatum were aquired on 8 section, (a 
total of 32 images per mouse), using a Zeiss AxioVision 2 epifluorescence microscope with a 63X 
objective. In order to automatically delineate the fibers, the images were first thresholded and 
subsequently quantified with an automatic counting-grid macro implemented in the Metamorph 
software (Molecular Devices). 
4.4.5. Quantification of striatal fiber density by fiber area measurement  
For analyzing the striatal fiber density in the 18 and 24 months old Ret/Pink1/Parkin groups of 
mice, a new method for quantifying striatal fibers was developed, that does not require manual 
thresholding of the images, hence being more automated and unbiased. Images were acquired as 
described above. Using in series of algorithms in the CellProfiler 2.0 software (Broad Institute), 
striosomes were first automatically identified as objects using segmentation which takes into 
account their size, shape, and intensity, and were excluded from the area to be analysed. Next, 
the striatal fibers were identified using a similar approach as for the striosomes. Finally, the total 
area of fibers was measured and divided by the image area not occopied by striosomes. Average 
fiber area/total area per mouse was used for the statistical analysis. 
4.4.6. Quantification of Soma Size of SN Neurons 
GIRK2 immunostained coronal sections were analyzed using a bright field microscope with a 
40× objective. Random cells were selected with stereological methods using the 
StereoInvestigator software. Five to seven animals per group were measured by circling cell soma 
of 149–275 cells per animal. 
4.4.7. Measurements of Dopamine Levels by HPLC 
Materials and Methods 101 

18 months old mice were sacrificed, brains were removed, snap-frozen, and the striata were 
dissected. The tissue was homogenized in 0.1 M perchloric acid containing 0.5 mM disodium 
EDTA and 50 ng/ml, 3,4-dihydroxybenzylamine as an internal standard, centrifuged at 50,000 g 
for 30 min, and filtered through a 0.22 μM PVDF membrane. Monoamines and their 
metabolites were separated on a reverse-phase ODS column (YMC-Pack, S-3 μM, 120 A; 
Stagroma AG, Reinach, Switzerland). The column temperature was maintained at 33°C. The 
mobile phase was 34% citric acid 0.1 M, 48% Na2HPO4 0.1 M, 18% methanol, 50 mg/l 
EDTA, and 45 mg/l sodium octylsulfate, pH 4.5. The flow rate was set at 0.45 ml/min. The 
potential settings of the analytical cell (model 5011; ESA Inc.) were +0.45 V (first electrode) and 
–0.3 V (second electrode). Monoamines and their metabolites were read as second-electrode 
output signal. 
4.4.8. Open field behavioral analysis 
Control and mutant mice, mice were subjected to open field behavioral assessment. 18 months 
old mice were housed individually in a room with 12 h/12 h reversed day-night cycle. All 
experiments were conducted during the night period in a quiet room with light of 12 lux. Mice 
were placed into a 59 cm×59 cm large arena for 20 min, they were filmed from above and their 
movement was tracked using EthoVision Pro 2.2. (Noldus, Sterling, USA). The experiment was 
repeated on the consecutive day and the average distance each mouse travelled during the two 
trials was determined. Experimental protocols were approved by the government of Oberbayern, 
Germany. 
 
4.5. Drosophila genetics and histology 
 
Table 4-12 Transgenic drosophila lines 
Allele Chromosome Description, source 
park25 3 Null allele by imprecise p-element excision, Leo Pallanck (USA) 
park25::24B-GAL4 3 park25 recombined with 24B-GAL4, Leo Pallanck (USA) 
park25::mef2-GAL4 3 park25 recombined with mef2-GAL4, Leo Pallanck (USA) 
park25::TH-GAL4 3 park25 recombined with TH-GAL4, Leo Pallanck (USA) 
park1 3 Null allele by imprecise p-element excision, Jongkyeong Chung (South Korea) 
Pink1B9 X Null allele by imprecise p-element excision, Jongkyeong Chung (South Korea) 
Pink1B9::24B-GAL4 X Pink1B9 recombined with 24B-GAL4, Alex Whitworth (UK) 
Pink1B::mef2-GAL4 X Pink1B9 recombined with mef2-GAL4, Alex Whitworth (UK) 
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24B-GAL4 3 Mesoderm-specific driver, Bloomington stock center #1767 
mef2-GAL4 3 Muscle-specific driver , Frank Schnorrer (Germany) 
TH-GAL4 3 Dopamine neuron-specific driver, Hiromu Tanimoto (Germany) 
UAS-DretMEN2A 2 Constitutively active Dret, Ross Cagan (USA) 
UAS-DretMEN2B 3 Constitutively active Dret, Ross Cagan (USA) 
4.5.1. Imaging and analysis of Drosophila eyes 
1-5 days old flies were anaesthetized by CO2, heads were removed and pictures of eyes were 
acquired using a Leica MZ 9.5 stereomicroscope equipped with a Leica DFC320 digital camera 
(LeicaMicrosystems, Wetzlar, Germany). Total eye area was determined using the ImageJ 
software (NIH, USA). 
4.5.2. Dissection and analysis of flight muscles 
Wings, head and abdomen were removed from CO2 anaesthesized flies. The thoraces were placed 
in PFA fixative solution for 15 minutes. Thoraces were bisected sagitally along the midline using 
a razor blade (Gillette) and placed in phalloidin staining solution for 30 min to 1 hour. After 
staining, thoraces were washed in PST-tween 2 x 10 minutes and mounted in Vectashield 
mounting medium. The dorsal longitudinal indirect flight muscles were imaged in a Leica SP2 
confocal laser scanning microscope using 20X and 63X objectives. 
4.5.3. Whole-mount immunostaining of brains and analysis of PPL1 dopamine neuron numbers 
Park25 mutant flies have reduced viability compared to wild type.  To increase the survival, the 
flies were fed with food enriched with yeast and glucose and were flipped every 3-4 days. After 
20-30 days, brains were dissected in PBS, fixed in PFA fixative solution for 1 hour and washed 3 
x 5 minutes in PBST. After washing, the brains were incubated with a tyrosine hydroxylase 
antibody (ab152, Abcam) diluted 1:200 in PBST with 5 % FCS over night at 4 °C. After the 
primary antibody incubation, the brains were washed 3 x 5 min in PBST, and incubated with an 
alexa488-coupled secondary antibody diluted 1:200 in PBST with 5 % FCS for 2 hours at RT, 
and again washed 3 x 5 min in PBST. The brains were mounted on coverglass with the posterior 
side facing upwards in Vectashield. Confocal Z section were acquired every 1 μm using a Leica 
SP2 confocal laser scanning microscope with a 20x objective. After 3D reconstruction using the 
ImageJ software (NIH), the neurons in the PPL1 cluster were counted in a blinded manner. 
4.5.4. Analysis of PPL1 neuron mitochondrial morphology 
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Brains of 2-4 day old flies were dissected and immunostained for tyrosine hydroxylase as 
described above, with the difference that a Cy3-coupled secondary antibody was used. The cells 
of the PPL1 cluster were imaged using a Zeiss spinning disc confocal microscope, Z-sections 
every 0,5 μm were acquired and deconvolved using Metmorph v7.6 software (Molecular 
Devices). The size of the mitochondria was measured by automated image analysis using Cell 
Profiler 2.0 (Broad Institute). 
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